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Abstract 
 
Solubility enhancement of poorly-soluble active pharmaceutical ingredients 
(APIs) remains a scientific challenge and poses a practical issue in the pharmaceutical 
industry. The emergence of pharmaceutical cocrystals has contributed another dimension 
to the diversity of crystal forms available at the disposal of the pharmaceutical scientist. 
That pharmaceutical cocrystals are amenable to the design principles of crystal 
engineering means that the number of crystal forms offered by pharmaceutical cocrystals 
is potentially greater than the combined numbers of polymorphs, salts, solvates and 
hydrates for an API. The current spotlight and early-onset dissolution profile (“spring-
and-parachute” effect) exhibited by certain pharmaceutical cocrystals draw attention to an 
immediate question: How big is the impact of cocrystals on aqueous solubility? The 
scientific literature and in-house data on pharmaceutical cocrystals that are 
thermodynamically stable in water are reviewed and analyzed for trends in aqueous 
solubility and melting point between the cocrystal and the cocrystal formers. There is 
poor correlation between the aqueous solubility of cocrystal and cocrystal former with 
respect to the API. The log of the aqueous solubility ratio between cocrystal and API has 
a poor correlation with the melting point difference between cocrystal and API. 
Structure-property relationships between the cocrystal and the cocrystal formers remain 
elusive and the actual experiments are still necessary to investigate the desired 
physicochemical properties. 
Crystal form (cocrystals, polymorphs, salts, hydrates and solvates) diversity is and 
will continue to be a contentious issue for the pharmaceutical industry. That the crystal 
xvi 
 
form of an API dramatically impacts its aqueous solubility (a fixed thermodynamic 
property) is illustrated by the histamine H2-receptor antagonist ranitidine hydrochloride 
and HIV protease inhibitor ritonavir. For more than a century, the dissolution rate of a 
solid has been shown to be directly dependent on its solubility, cēterīs paribus. A century 
later, it remains impossible to predict the properties of a solid, given its molecular 
structure. If delivery or absorption of an API are limited by its aqueous solubility, 
aqueous solubility then becomes a critical parameter linking bioavailability and 
pharmacokinetics of an API. Since the majority of APIs are Biopharmaceutical 
Classification System (BCS) Class II (low solubility and high permeability) compounds, 
crystal form screening, optimization and selection have thus received more efforts, 
attention and investment. Given that the dissolution rate, aqueous solubility and crystal 
form of an API are intricately linked, it remains a scientific challenge to understand the 
nature of crystal packing forces and their impact upon physicochemical properties of 
different crystal forms. Indeed, the selection of an optimal crystal form of an API is an 
indispensable part of the drug development program. The impact of cocrystals on crystal 
form diversity is addressed with molecular and ionic targets in ellagic acid and lithium 
salts. A supramolecular heterosynthon approach was adopted for crystal form screening. 
Crystal form screening of ellagic acid yields molecular cocrystals, cocrystal 
solvates/hydrates and solvates. Crystal form screening of lithium salts (chloride, bromide 
and nitrate salts) afforded ionic cocrystals and cocrystal hydrates. 
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Chapter 1. Molecular crystal forms 
  
“…, crystals should not be regarded as chemical graveyards.”1 
Michael J. Zaworotko 
 
1.1 Preamble 
 Scientists have a natural inclination to correlate structure with properties. It is 
owing to the curiosity (and I must add persistence) of the individual to make new 
discoveries and relate them to what is known. I was trying to recall my first chemistry 
lesson ever but strangely enough, I could not. It must have been a lesson on the periodic 
table. Afterall, the periodic table provides a systematic classification of all known 
elements into different horizontal rows (periods) and vertical columns (groups) to help 
chemists to rationalize the properties of these elements as atoms. In short, the periodic 
table is useful in correlating the electronic configuration (electronic structure) of atoms 
with their properties. Dmitri Ivanovich Mendeleev is credited for creating the first 
version of the periodic table.2 With the table, he was successful in predicting the 
properties of elements that have yet to be discovered and was honoured with the 
radioactive “mendelevium”, named after him. Early scientists have demonstrated success 
in establishing structure-property relationships in atoms. 
 Linking atoms together, we can have ions or molecules. According to the Oxford 
English Dictionary,3 a molecule is (1) one of the minute discrete particles of which 
material substances were thought to be composed; (2) the smallest unit of a chemical 
compound that can take part in the reactions characteristic of that compound; (3) a group 
2 
 
of atoms chemically bonded together and acting as a unit. One may think of a molecule 
as an assembly of atoms held together by an attractive force. Following the introduction 
to acids, bases and general organic chemistry, the floodgates were opened to a massive 
amount of information on the states of matter. The kinetic theory of gases assumes 
negligible interactions between gaseous molecules.4 Liquids and solids enter the picture 
when the interactions between molecules are significant and cannot be ignored. Moving 
along a homologous series of alkanes, gases, liquids and solids are encountered, 
characterized by their boiling points or melting points.5-6 In a way, this collection of data 
enabled us to associate structural features (of the molecules) with properties. There is an 
urge to analyze for trends in the physical properties across the same class of compounds 
and correlate the molecular structure with their properties. 
 When the intermolecular forces of attraction are sufficiently strong, molecules 
aggregate into a solid. The controlled aggregation in an organized mode results in a 
crystalline solid. How much do we know about the solid as a crystalline material? 
 
1.2 From molecules to crystals 
 “The crystal is … the supermolecule par excellence.”7 A crystal is a material 
made up of atoms, molecules or ions that are organized in an orderly periodic 
arrangement that repeats in three spatial directions. “While analyzing crystal structures in 
terms of intermolecular interactions, one recognizes certain repetitive structural units. 
These are typically small in size and are composed of specific molecular functionalities 
and their resulting interactions arranged in specific ways. The identification of these 
structural units is somewhat subjective but they are important in that they may be 
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associated with particular crystal packing characteristics.”8 Thus molecules recognize 
themselves in the solid state and organize themselves through molecular recognition 
events so that one can think of the smallest repeating unit as the unit cell. The 
propagation of the unit cell along the three crystallographic axes illustrates a crystal. 
However, the same molecules can organize themselves with different molecular 
recognition events to achieve another crystal. This gives rise to polymorphism. McCrone 
describes a polymorph9 as “a solid crystalline phase of a given compound resulting from 
the possibility of at least two different arrangements of the molecules of that compound 
in the solid state.” 
 
1.3 Allotropism 
 The phenomenon and consequences of at least two different arrangements of the 
constituents of the same compound in the solid state, is perhaps best illustrated by the 
element carbon.10  Carbon exists in the form of diamond, graphite, lonsdaleite, C6011 
(buckminsterfullerene or buckyball), C540, C70, single-walled carbon nanotube and 
amorphous carbon. In diamond, each carbon atom is bonded to four other carbon atoms 
covalently in a tetrahedral arrangement. The overall structure is a 3-periodic diamondoid 
(dia) network of carbon atoms featuring six-membered carbon rings in the stable chair 
conformation that results in the hardness of diamond.12 This hardness makes diamond an 
excellent abrasive and used industrially in cutting and drilling operations. In graphite, 
each carbon atom is covalently bonded to three other carbon atoms in a plane, forming a 
(6,3) honeycomb net. Each carbon atom has four valence electrons and contributes one 
electron to a delocalized system of π-electron density above and below the plane, 
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allowing these delocalized electrons to move freely throughout the plane. Hence graphite 
becomes a conductor of electricity along the planes of the carbon atoms. The layer 
structure of graphite13 enables it as a lubricant. Using elemental carbon as an example, 
diamond and graphite bring forth the contrast in properties generated by their distinct 
spatial arrangements (crystal packing) of the carbon atoms. 
 
1.4 Polymorphism of molecular crystals 
 The first example of polymorphism of molecular compounds was reported by 
Liebig and Wöhler14 as early as 1832 when they described the slow cooling of a “boiling 
hot” aqueous solution of benzamide which produced white silky needles that transformed 
to rhombic crystals. They were alerted by the changes in the morphology of the crystal. 
The single crystal X-ray structure of benzamide (Form I)15 was reported in 1959. David16 
and Blagden17 pursued the structure solution of benzamide (Form II) using powder X-ray 
diffraction techinques in 2005 until Form III18 was reported four years later. The 
polymorphism of benzamide was identified by the keen eye for detail of Liebig and 
Wöhler but the lack of control in polymorphic selectivity from a crystallization process 
had been a barrier in the solid state characterization of the polymorphs. 
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Figure 1-1. Crystal Packing of Benzamide (Form I, top left, Form II, bottom left, 
Form III, bottom right) and the amide dimer supramolecular homosynthon present 
in all three polymorphs (top right). 
 
 In the crystal structures of benzamide Forms I, II and III, a supramolecular tape 
established by the lateral stacking of the amide dimers, is present in all three polymorphs. 
However, the relative orientation of these supramolecular tapes is different amongst the 
three polymorphs and hence the cause of the polymorphic behaviour of benzamide. The 
meticulous efforts to unravel the polymorphs of a simple molecule in benzamide, 
highlights the alertness of the individual and the challenges in understanding and 
controlling the crystallization conditions.  
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Figure 1-2. The conformations of ritonavir Form I (top) and Form II (bottom). 
 
 166 years later, the lack of control in polymorphic selectivity from a 
crystallization process was thrust onto centre stage. Ritonavir (HIV-1 protease inhibitor) 
is a Biopharmaceutical Classification System19 (BCS) Class 4 drug with low solubility 
and low permeability. One crystal form of ritonavir20 (Form I) was known since its 
development and production of 240 lots of Norvir capsules without the problem of phase 
transformation. Alarm was raised when several lots of the capsules failed a series of 
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dissolution experiments, powder X-ray diffraction revealed the appearance of a 
polymorph (Form II). The crystal structures21 of Forms I and II reveal the compound 
exists in different conformations around the carbamate in the solid state. The subtle 
change in the conformation results in crystals with a decrease in aqueous solubility. In 
addition, the presence of Form II in the original capsule formulation decreases the 
bioavailability. The emergence of undesired Form II had an instant impact on the 
manufacturing and clinical fronts. Form II appeared according to Ostwald’s Law of 
Stages but there was no crystallization strategy and lack of knowledge at that time to 
prevent its formation.  
Table 1-1. Solubility of ritonavir polymorphs at 5°C. 
EtOH/H2O 99/1 75/25 
Form I (mg/mL) 90 170 
Form II (mg/mL) 19 30 
 
 In hindsight, polymorphism is not the problem, the issue lies in the lack of 1) 
control of the crystallization conditions and 2) a proactive approach22 to explore the 
crystal form landscape of the API in the marketed product. 
 
1.5 Concomitant polymorphism 
 To understand the relationship between structure and properties of crystals, 
polymorphic systems are ideal since any changes in the properties of the crystal form is 
invariably due to its structure (crystal packing), cēterīs paribus. Indeed, the intrigue of 
polymorphism is best captured in 5-methyl-2-[(2-nitrophenyl)amino]-3-
thiophenecarbonitrile,23 also known as ROY for its red, orange and yellow crystals. To 
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date, it has ten polymorphs (1. R, 2. Y, 3. ON, 4. OP, 5. YN, 6. ORP, 7. RPL, 8. Y04, 9. 
YT04 and 10. R05, numbered in order of discovery and named in terms of colour and 
morphology). Of these, seven polymorphs have been characterized by single crystal X-
ray crystallography at ambient conditions (20°C to 23°C) to elucidate the origins of its 
polymorphic behaviour and difference in colour. X-ray analysis of ROY polymorphs 
highlighted the torsion angle θ as an important variable, producing distinct conformations 
of ROY in the crystal packing. π-conjugation increases between the thiophene and 
benzene rings as the torsion angle θ nears zero, resulting in a red shift of the visible 
absorption spectrum. 
 
 
Figure 1-3. Molecular structure of ROY. 
 
Table 1-2. Melting points and torsion angles of ROY polymorphs. 
Form R Y ON OP YN ORP YT04 
mp (°C) 106.2 109.8 114.8 112.7 99 97 106.9 
θ (°) 21.7 104.7 52.6 46.1 104.1 39.4 112.8 
 
 The pure melt of ROY yields several polymorphs simultaneously upon cooling to 
near room temperature. Mixtures of polymorphs are also obtained from crystallization in 
methanol. All known polymorphs of ROY have been crystallized near ambient 
N
N
O O
H
S
CN

9 
 
conditions. The concomitant polymorphism24 of ROY makes it a challenging model 
system to understand the relationship between nucleation and crystal growth of 
polymorphs in general. Furthermore, their kinetic stability (at ambient conditions) allows 
them to be isolated and studied for their stability relationships. The relative Gibbs free 
energy of seven ROY polymorphs were calculated using data collected from differential 
scanning calorimetry experiments25-26 to plot an energy versus temperature diagram and 
reveal the stability order of ROY polymorphs and their monotropic or enantiotropic 
relationships.27-28 The goal is to dictate polymorphic selectivity through a crystallization 
process and ultimately gain the control of selective crystallization of the desired 
polymorph in a complicated system. 
 
1.6 Enantiotropy and Monotropy 
 The relative stability of two polymorphs depends on their Gibbs free energies. 
 
G = H – TS 
(G = Gibbs free energy, H = enthalpy, T = temperature in K, S = entropy) 
 
 When the stability order of polymorphs is invariant of temperature, the 
polymorphs are monotropic. When the stability order of polymorphs changes with 
temperature, they become enantiotropic polymorphs. The knowledge of the enantiotropic 
or monotropic relationship between different polymorphs requires the generation of 
energy versus temperature diagram of the polymorphic system. This diagram can be used 
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as a map to direct the crystallization process to achieve a desired polymorph at the 
expense of the undesired polymorph. For a dimorphic system, there are four possibilities: 
 
1) The desired thermodynamically stable form is in a monotropic system. Phase 
transformation will not occur to generate another form hence precautions are not 
necessary to guard against such a transformation. 
 
2) The desired thermodynamically stable form is in an enantiotropic system. Precautions 
must be exercised to maintain the thermodynamic conditions at which the Gibbs free 
energy of the desired polymorph is lower than that of the other. 
 
3) The desired thermodynamically metastable form is in a monotropic system. A 
kinetically controlled phase transformation will occur to generate the undesired 
thermodynamically stable form. Precautions must be exercised to retard the kinetics 
of the transformation by employing extreme conditions such as very low 
temperatures, very dry conditions and storage in the dark. 
 
4)  The desired thermodynamically metastable form is in an enantiotropic system. The 
generation of the energy versus temperature diagram of the polymorphic system will 
reveal the temperature range at which the Gibbs free energy of the desired form is 
lower than that of the other, to obtain and maintain this desired form. 
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1.7 Remarks 
  “There are many mysteries of nature that we have not solved. Hurricanes, for 
example, continue to occur and often cause massive devastation. Meteorologists cannot 
predict months in advance when and with what velocity a hurricane will strike a specific 
community. Polymorphism is a parallel phenomenon. We know that it will probably 
happen. But not why or when. Unfortunately, there is nothing that we can do today to 
prevent a hurricane from striking any community or polymorphism from striking any 
drug.”29 
Dr. Eugene Sun 
 
This underscores the necessity for due diligence in solid form screening.30 
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Chapter 2. The Impact of Cocrystal on Aqueous Solubility 
 
2.1 Preamble 
 Solubility enhancement31-32 of poorly-soluble APIs33-34 remains a scientific 
challenge and poses a practical issue in the pharmaceutical industry. The emergence35 of 
pharmaceutical cocrystals has contributed another dimension to the diversity of crystal 
forms available for pharmaceutical development. The long-standing reliance of the 
pharmaceutical industry and regulatory authorities on crystal forms and the “spring-and-
parachute”36-type dissolution profile uniquely exhibited by certain pharmaceutical 
cocrystals draw attention to an immediate question: How big is the impact of cocrystals 
on aqueous solubility? The scientific literature and in-house data on pharmaceutical 
cocrystals that are thermodynamically stable in water are reviewed and analyzed for 
trends in aqueous solubility and melting point between the cocrystal and the cocrystal 
formers. There is poor correlation between the aqueous solubility of cocrystal and 
cocrystal former with respect to the API. The log of the aqueous solubility ratio between 
cocrystal and API has a poor correlation with the melting point difference between 
cocrystal and API. Structure-property relationships between the cocrystal and the 
cocrystal formers remain elusive and the actual experiments are still necessary to 
investigate the desired physicochemical properties. 
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2.2 Biopharmaceutical Classification System (BCS) 
 A critical parameter deciding the fate of any API is its aqueous solubility. Hence 
to increase drug solubility while maintaining a stable solid form is often an integral part 
of a pharmaceutical development process. This goal is imperative since solubility and 
permeability are the two criteria used to illustrate oral absorption of a drug according to 
the BCS.19 BCS class II (low solubility, high permeability) drugs are limited in oral 
absorption by their solubility. This class of drugs is currently estimated to account for 
about 30% of commercial and developmental drugs37. BCS class I (high solubility, high 
permeability) is the ideal scenario for any API to be in. Increased solubility can result in a 
significant improvement of oral absorption, leading to higher bioavailability, pushing a 
drug from BCS class II to BCS class I. This can be achieved via pharmaceutical 
cocrystals38, which have emerged and established itself as a promising methodology to 
modify important physicochemical properties of poorly water soluble drugs, such as 
solubility, dissolution rate and bioavailability, to the extent that the pharmaceutical 
industry cannot afford not to explore. Indeed crystal form screening of APIs have 
traditionally been restricted to polymorphs, salts and solvates (including hydrates). 
Pharmaceutical cocrystals are also possible for nonionizable39, weakly acidic40 and 
weakly basic41 drugs which prevent and restrict the opportunity of a salt screen 
respectively, and present a viable option for solubility enhancement without changing the 
molecular structure of the drug. 
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2.3 Noyes-Whitney Equation 
 The Noyes-Whitney equation42-43 dictates the dissolution profile of all substances, 
at least until the dissolution of cocrystals was reported. It states “the rate at which a solid 
substance dissolves in its own solution is proportional to the difference between the 
concentration of that solution and the concentration of the saturated solution”. This has 
practical relevance for the dissolution profile. A solid with high solubility will boast a 
high initial rate of dissolution. A solid with low solubility will exhibit a low initial rate of 
dissolution and take a longer time to reach maximum concentration. There will not be a 
solid with low solubility but demonstrate a high initial rate of dissolution or vice versa. 
With cocrystals, there can be a sudden spike in concentration (“spring-and-parachute” 
effect) of the API followed by a precipitous dip to a level similar to that of the pure API. 
This is achieved by a poorly water soluble antidepressant Prozac®.36 The powder 
dissolution profiles of cocrystals of fluoxetine hydrochloride were measured and each 
cocrystal has its unique dissolution properties. Obviously, there are several controls such 
as temperature, stirring rate, particle size distribution (PSD), volume and type of 
dissolution media. These factors are meant to mitigate the effects of diffusion 
phenomenon and surface area. The solubility of cocrystals had been reported in a variety 
of dissolution media, including 0.1 N HCl, fasted simulated intestinal fluids (FaSIF) and 
water. The dissolution media and context used for performing dissolution experiments 
can also change the outcome of the experiment. This was exemplified by the celecoxib44 
nicotinamide cocrystal. Most studies reported the dissolution profile over time. Particle 
size control via sieving of samples was reported occasionally. There was also no mention 
of controls in some reports. This highlights the wide range of experimental parameters 
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that are adopted in solubility experiments which can be adjusted to achieve the necessary 
information. 
 
2.4 Thermodynamic versus apparent solubility 
 There are several pointers to consider when consulting solubility data45. The first 
is equilibrium versus apparent solubility measurements. Apparent solubility 
measurements are approximate data points usually based on one measurement at one time 
point. It is unknown if the solid material is thermodynamically stable in the system or if 
the system has reached equilibrium in the time frame of the experiment unless additional 
experiments are conducted to verify the phase purity of the material before and after each 
dissolution experiment. For equilibrium solubility, multiple data points are recorded at 
different time points to ensure the system has attained equilibrium, by observation of a 
plateau in the concentration-time plot, which is also referred to as a powder dissolution 
profile. Powder dissolution rates can be influenced by PSD since a smaller PSD affords a 
greater surface area in contact with the dissolution medium, given the same mass of 
material. The next factor is phase change during the experiment, as mentioned earlier 
about thermodynamic stability. When there is a change in the phase purity of the solid 
material, the resultant solubility data may be irrelevant to the starting material in the 
experiment. Phase transformation can be detected by powder X-ray diffraction (PXRD) 
and differential scanning calorimetry (DSC). They are typically indicated by the 
crystallization of a less soluble material after a dramatic plunge in concentration during 
the collection of solubility measurements at various time points. Hence the maximum 
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solubility observed over a certain time period is reported along with the time of 
occurrence but this is not an equilibrium solubility measurement. An analysis of the solid 
material remaining after the experiment is required to confirm any phase transformation. 
 Solubility studies had been conducted to correlate the aqueous solubilities of 
cocrystals and their respective cocrystal formers. Success in these studies will pave the 
way to a solubility-guided strategy46 towards cocrystal screening. Alternatively, the 
origin of pharmaceutical cocrystals47 is the product of an approach based on the 
understanding and implementation of supramolecular synthons.48 A solubility-guided 
strategy towards cocrystal screening for solubility enhancement is indeed very attractive. 
Should aqueous solubility become a transferable property, all cocrystal former libraries 
will only include those with high aqueous solubility and significantly reduce the number 
of cocrystal screening experiments. 
 
2.5 Solubility and Melting Point 
 Solubility is a fixed thermodynamic property of a crystal form. From a 
thermodynamic standpoint, the Gibbs free energy of solution is the summation of the 
lattice energy and solvation energy in an aqueous system. Going from a pure crystalline 
API to a cocrystal, the Gibbs free energy of solution is obviously going to change since 
the cocrystal is a new composition of matter and not a physical mixture of two solids. 
The hydration energy of both components (as a cocrystal or a physical mixture) is 
assumed to be a constant as they retain their molecular integrity in solution. But the 
lattice energy changes since the cocrystal is a new crystalline material. A stable crystal 
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form with high lattice energy is unlikely to disintegrate and dissolve in solution easily. 
Likewise, a less stable crystal form with low lattice energy is more likely to disintegrate 
and dissolve in solution readily. Since melting point is a direct manifestation of the lattice 
energy and also an experimentally verifiable physical property of a crystalline solid that 
is easily obtainable, melting point may have a better correlation with the experimentally 
determined solubility measurements. In fact, if the inverse relationship between lattice 
energy and thermodynamic solubility is a simple one, solubility enhancement of an API 
upon cocrystal formation should be accompanied by melting point depression, observable 
by the difference in melting point between the cocrystal and the API. 
 To search for trends in solubilities of cocrystals, we undertook the endeavor to 
investigate the aqueous solubilities of cocrystals, eliminating systems where a solvent-
mediated phase transformation occurred. 
 
2.6 Trends in Aqueous Solubility of Cocrystals 
 Dissolution experiments of crystalline itraconazole (95% of all crystalline 
particles < 10 μm), commercial Sporanox® beads (amorphous itraconazole) and three 
itraconazole cocrystals (succinic acid, L-malic acid and L-tartaric acid) were conducted in 
solutions of 0.1 N HCl at 25°C. All the cocrystals demonstrated higher solubility than 
crystalline itraconazole. The solubility of the succinic acid cocrystal was about 2 × 10-4 
M, while the solubilities of the L-malic acid and L-tartaric acid cocrystals were about 7 × 
10-4 M which rivals the commercial amorphous Sporanox formulation. These cocrystals 
recorded a sustained increase in concentration ranging from 4- to 20-fold higher than that 
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of crystalline itraconazole49. This provides an early example of the solubility 
improvements that cocrystals can deliver. 
Table 2-1. Solubility data for itraconazole cocrystals.b 
Cocrystal [CCF] (mg/mL) [API] (M) [CC] (M) 
Itraconazole 
Succinic acid 
76.9a ~(1/4)(2×10-4) ~2 × 10-4 
Itraconazole 
L-malic acid 
363.5a ~(1/20)(7×10-4) ~7 × 10-4 
Itraconazole 
L-tartaric acid 
1390a ~(1/20)(7×10-4) ~7 × 10-4 
aValues are obtained from the Merck Index. bPhase transformation during the 
dissolution experiment is not reported. 
 
 The dissolution profiles of fluoxetine HCl36 and three fluoxetine HCl cocrystals 
(benzoic acid, succinic acid and fumaric acid) were monitored in water at 20°C for 120 
minutes using ultraviolet spectroscopy (UV) at 227 nm. The samples were sieved to 
achieve a PSD of 53-150 μm. About 800 mg of sample were introduced to 30 mL of 
water at a stirring rate of 144 rpm. Any remaining solids after the dissolution experiment 
were filtered, dried in vacuum and analyzed by powder x-ray diffraction (PXRD). The 
solubility of fluoxetine HCl was 11.4 mg/mL. The solubility of the benzoic acid cocrystal 
was lower at 5.6 mg/mL while the fumaric acid cocrystal was higher at 14.8 mg/mL. The 
succinic acid cocrystal recorded a peak solubility of 20.2 mg/mL after about 1 minute 
before decreasing to a concentration which nears that of fluoxetine HCl. The validity of 
these results is confirmed by PXRD analysis of the undissolved solids matching those of 
the starting phases for fluoxetine HCl, benzoic acid and fumaric acid cocrystals. PXRD 
also confirmed the identity of the undissolved solids after dissolution of the succinic acid 
cocrystal, to be fluoxetine HCl, highlighting that the cocrystal dissociated and 
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recrystallized to fluoxetine HCl under the experimental conditions. This series of three 
cocrystals is unique in providing an example each of increasing (fumaric acid cocrystal) 
and decreasing (benzoic acid cocrystal) the aqueous solubility as well as being the first 
example (succinic acid cocrystal) of the “spring-and-parachute” effect. 
Table 2-2. Solubility data for fluoxetine hydrochloride cocrystals. 
Cocrystal [CCF] 
(mg/mL) 
[CC] (mg/mL) Conversion 
during 
experiment 
CC mp (°C) 
Fluoxetine HCl 
Benzoic acid 
3.4a 5.6 No 131.46 
Fluoxetine HCl 
Succinic acid 
76.9a 20.2 Yes 134.08 
Fluoxetine HCl 
Fumaric acid 
6.3a 14.8 No 161.06 
aValues are obtained from the Merck Index. [API]=11.4 mg/mL. API mp=157.18°C. 
 
 A developmental cancer candidate compound50 (Pfizer 1), a potent and selective 
ErbB2 inhibitor, is a weak base with an aqueous solubility of 0.0008 μmol/mL. 20 crystal 
forms of acid-base pairs were obtained after a salt screen. Three of these; a 
sesquisuccinate (neutral, 0.79 μmol/mL), a dimalonate (mixed ionic and zwitterionic, 
3.83 μmol/mL) and a dimaleate (salt, 10.4 μmol/mL), were selected for development. The 
location of the protons is probed by X-ray structural analysis and confirmed by cross 
polarization magic angle spinning (CPMAS) 15N nuclear magnetic resonance (NMR) 
spectroscopy. There was no discussion on the experimental conditions involving 
solubility measurements. However, this is the first example of a cocrystal that exhibited 
an aqueous solubility approximating 3 orders of magnitude higher than that of the pure 
drug. 
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Table 2-3. Solubility data for Pfizer 1 succinic acid cocrystal.b 
Cocrystal [CCF] (mg/mL) [CC] (μmol/mL) CC mp (°C) 
Pfizer 1 
Succinic acid 
76.9a 0.79 143 
aValue is obtained from the Merck Index. bPhase transformation during the 
dissolution experiment is not reported. [API]=0.0008 μmol/mL. API mp=167°C. 
 
 Norfloxacin51 is a poorly water soluble fluoroquinolone antibacterial drug. An 
isonicotinamide cocrystal and three salts with succinic acid, malonic acid and maleic acid 
were prepared and structurally characterized. Solubility studies were performed by 
suspending about 21 mg of sample in 2.5 mL of water, maintained at 25°C (±1) in a 
laboratory oven for 72 hours at a stirring rate of 300 rpm using absorbance measured at 
276 nm. The succinic acid, malonic acid and maleic acid salts have an apparent solubility 
of 6.60, 3.90 and 9.80 mg/mL. The apparent solubility of norfloxacin is 0.21 mg/mL 
while that of the isonicotinamide cocrystal is 0.59 mg/mL. This cocrystal resulted in a 
modest 3-fold increase in solubility. 
Table 2-4. Solubility data for norfloxacin isonicotinamide cocrystal solvate.a 
Cocrystal [CCF] (mg/mL) [CC] (mg/mL) CC mp (°C) 
Norfloxacin 
Isonicotinamide 
Chloroform solvate 
192 0.59 180 
aPhase transformation during the dissolution experiment is not reported. 
[API]=0.21 mg/mL. API mp=221°C. 
 
 AMG 51752, a transient receptor potential vanilloid 1 antagonist (TRPV1) 
developed for the treatment of chronic pain, possesses an aqueous solubility of 5 μg/mL 
as the free base. A total of 21 cocrystals were reported on two occasions. Solubility 
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measurements were taken in fasted simulated intestinal fluid (FaSIF) at 25°C within a 24 
hour timeframe. There was no reported control of particle size. Of these cocrystals, there 
are 6 cocrystals with trans-cinnamic acid, 2,5-dihydroxybenzoic acid, 2-hydroxycaproic 
acid, benzoic acid, benzamide and cinnamide, that did not undergo any phase 
transformation during the duration of the experiment. The solubilities of the cocrystals 
are 1, 2, 3, 21, 12.6 and 6.3 μg/mL respectively53-54. The benzoic acid cocrystal reported a 
four-fold increase in solubility. 
Table 2-5. Solubility data for AMG517 cocrystals. 
Cocrystal [CCF] 
(mg/mL) 
[CC] (μg/mL) Conversion 
during 
experiment 
CC mp (°C) 
AMG 517 
trans-cinnamic acid 
0.23a 1 No 204 
AMG 517 
2,5-
dihydroxybenzoic 
acid 
22b 2 No 229 
AMG 517 
2-hydroxycaproic 
acid 
32c 3 No 130 
AMG 517 
Benzoic acid 
3.4d 21 No 146 
AMG 517 
Benzamide 
13.5d 12.6 No 164 
AMG517 
Cinnamide 
1.37 6.3 No 184 
aLiterature value. bValue is obtained from the Handbook of Aqueous Solubility 
Data. cValue is calculated from Scifinder. dValues are obtained from the Merck 
Index. [API]=5 µg/mL. API mp=230°C. 
 
 Ethenzamide, a nonsteroidal anti-inflammatory drug (NSAID) for the treatment of 
moderate pain, forms polymorphic cocrystals55 with gentisic acid with three distinct 
crystalline modifications. Dissolution experiments were carried out at 25°C for 
ethenzamide and the three polymorphs. The equilibrium solubilities for ethenzamide and 
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the cocrystal (Form 1) were estimated to be 0.0344 and 0.0365 mg/mL. There was no 
solubility enhancement in this example. 
Table 2-6. Solubility data for ethenzamide gentisic acid cocrystal.b 
Cocrystal [CCF] (mg/mL) [CC] (mg/mL) CC mp (°C) 
Ethenzamide 
Gentisic acid Form 
I 
22a 0.0365 100.65 
aValue obtained from the Handbook of Aqueous Solubility Data. bPhase 
transformation during the dissolution experiment is not reported. 
[Ethenzamide]=0.0344 mg/mL. Ethenzamide mp=132°C. 
 
 Hexamethylenebisacetamide is used in the treatment of myelodysplastic 
syndrome and resistant acute myelogenous leukemia. A pyridine derivative56 (A) was 
prepared and forms five cocrystals with succinic acid, adipic acid, suberic acid, sebacic  
acid and dodecanedioic acid. Crystal structure analysis reveals that the linear diacids 
serve as spacer molecules such that the increase in length of the crystallographic c axis in 
space group P1ത is a reflection of the increasing number of carbon atoms from succinic 
acid to dodecanedioic acid. As the melting point of the diacid decreases from succinic 
acid to dodecanedioic acid, the cocrystals follow the same trend. The aqueous solubilities 
of the cocrystals also decrease as the aqueous solubilities of the diacids decreases. 
However, this is not a common occurrence and has been attributed to the crystal packing 
of the cocrystals. Dissolution experiments were conducted with A and its five cocrystals 
by stirring excess cocrystal solid phase in water (25°C). The concentration of A was 
monitored by UV spectroscopy (λmax = 236.4 nm). 
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Table 2-7. Solubility data for cocrystals of hexamethylenebisacetamide derivative 
(A).a 
Cocrystal [CCF] (mg/mL) [CC] (mg/mL) CC mp (°C) 
A·succinic acid 76.9 167.18 186 
A·adipic acid 14.4 117.3 165 
A·suberic acid 1.6 92.042 158 
A·sebacic acid 1 12.109 148 
A·dodecanedioic 
acid 
0.03 7.2459 146 
aPhase transformation during the dissolution experiment is not reported. [A]=70.24 
mg/mL. A mp=181°C. 
 
  Lamotrigine is marketed as Lamictal® by GlaxoSmithKline for oral 
administration as a conventional or chewable tablet for the treatment of epilepsy and 
psychiatric disorders such as bipolar disorder. Ten crystal forms of lamotrigine were 
reported: lamotrigine methylparaben cocrystal form I (1:1) (1), lamotrigine 
methylparaben cocrystal form II (1:1) (2), lamotrigine nicotinamide cocrystal (1:1) (3), 
lamotrigine nicotinamide cocrystal monohydrate (1:1:1) (4), lamotrigine saccharin salt 
(1:1) (5), lamotrigine adipate salt (2:1) (6), lamotrigine malate salt (2:1) (7), lamotrigine 
nicotinate dimethanol solvate (1:1:2) (8), lamotrigine dimethanol solvate (1:2) (9) and 
lamotrigine ethanol monohydrate (1:1:1) (10). Dissolution experiments were performed 
on 2, 3, 4 and 5 in deionized water (25°C) and 0.1 M HCl (37°C). The samples were 
sieved to achieve a PSD between 53 μm and 75 μm. 100 mg of samples were introduced 
into 100 mL of water while 500 mg of samples were introduced into 50 mL of 0.1 M HCl. 
The slurries were stirred at a rate about 200-300 rpm. Samples were filtered with a 0.45 
μm syringe filter and the concentration was determined using UV spectroscopy. The 
maximum concentration of 2, 3, 4, 5 and pure lamotrigine were 0.21, 0.30, 0.23, 0.45 and 
0.28 mg/mL respectively. PXRD analysis of the remaining solid after dissolution 
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confirmed 2 and 5 were the same solid phase while 3 and 4 converted to a hydrated form 
of lamotrigine57. 
Table 2-8. Solubility data for lamotrigine cocrystals. 
Cocrystal [CCF] 
(mg/mL) 
[CC] (mg/mL) Conversion 
during 
experiment 
CC mp (°C) 
Lamotrigine 
Methylparaben 
Form II 
2.5a 0.21b No 162.40 
Lamotrigine 
Nicotinamide 
1000a 0.30b Yes 167.23 
Lamotrigine 
Nicotinamide 
Monohydrate 
1000a 0.23b Yes 174.81 
aValues are obtained from the Merck Index. Maximum [API] 
observed=0.28 mg/mL. API mp=221°C. 
 
 The solubility of cytosine cocrystals58 with oxalic acid, malonic acid and succinic 
acid were measured by gravimetric method at 15, 25, 40 and 60 °C. The solubility of 
cytosine and its oxalic acid, malonic acid and succinic acid cocrystals were about 6, 4, 20 
and 7 mg/mL respectively. 
Table 2-9. Solubility data for cytosine cocrystals.b 
Cocrystal [CCF] (mg/mL) [CC] (mg/mL) CC mp (°C) 
Cytosine 
Oxalic acid 
98.1a ~4 270.2 
Cytosine 
Malonic acid 
1538a ~20 219.2 
Cytosine 
Succinic acid 
76.9a ~7 249.5 
aValues are obtained from the Merck Index. [API]=7.69 mg/mL.a bPhase 
transformation during the dissolution experiment is not reported. API 
mp=320°C(dec.). 
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 Pterostilbene is a dimethylated analogue of resveratrol59 that forms cocrystals 
with caffeine and carbamazepine. Three cocrystals60 were obtained: caffeine pterostilbene 
cocrystal (Form I and Form II) and carbamazepine pterostilbene cocrystal. Dissolution 
experiments were performed for caffeine pterostilbene cocrystal (Form I) and the 
carbamazepine pterostilbene cocrystal by slurrying in water for 72 hours. Samples were 
filtered with a 0.2 µm nylon filter and analyzed via a 96 well quartz plate using UV 
spectroscopy at 275 nm for carbamazepine. 
Table 2-10. Solubility data for pterostilbene cocrystals. 
Cocrystal [CCF] 
(mg/mL) 
[CC] (mg/mL) Conversion 
during 
experiment 
CC mp (°C) 
CBZ 
Pterostilbene 
0.021 0.0085 No 134 
Caffeine 
Pterostilbene 
Form I 
0.021 0.56 Yes 114 
[CBZ]=0.056 mg/mL. CBZ mp=190°C. 
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In-house studies 
Table 2-11. Molecular structures of phenolic acids used in this study and their three 
letter code. 
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 Tables 2-11 to 2-15 represent different categories of molecules based on different 
functional groups to facilitate cocrystal screening and preparation via a supramolecular 
heterosynthon approach. In-house dissolution experiments were performed for cocrystals 
of epigallocatechin-gallate, protocatechuic acid, coumaric acid, caffeic acid, gallic acid, 
ferulic acid, caffeine and (±)baclofen. All samples were prepared and sieved with ASTM 
standard sieve to achieve a PSD between 53 μm and 75 μm. The dissolution experiments 
were done in water at room temperature with the exception of (±)baclofen cocrystals at 
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36.9°C. Residual solids at the end of the dissolution experiments were analyzed with 
powder X-ray diffraction to ensure the integrity of the cocrystal solid phase. 
Table 2-12. Polyphenols used in this study and their three letter code. 
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Table 2-13. Pyridines, Purines and their three letter code. 
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Table 2-14. Zwitterions and their three letter code. 
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Table 2-15. Molecules with carbonyl groups and their three letter code. 
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 Many of these cocrystals routinely contain two components that can be 
considered as APIs in their own right based on their pharmacological properties. Thus the 
description of API and cocrystal former becomes interchangeable. For the correlation of 
the properties of the cocrystals, CCF1 will be used to denote the API while CCF2 will be 
denoted as the cocrystal former. 
Table 2-16. Aqueous solubility and melting point for target molecules. 
CCF1 [CCF1] (mg/mL) CCF1 mp (°C) 
Epigallocatechin gallate (EGCG) 23.6 140 
Protocatechuic acid (PCA) 10.67 200 
Coumaric acid (COU) 0.789 210 
Caffeic acid (CFA) 0.485 223 
Gallic acid (GAL) 11.49 258 
Ferulic acid (FER) 0.6 168 
Caffeine (CAF) 21.7 238 
(±)-baclofen (BAC) 5 206 
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Table 2-17. Solubility data for in-house cocrystals. 
Cocrystal Refcode 
(CCF1CCF2) 
[CCF2] (mg/mL) [CC] (mg/mL) CC mp (°C) 
EGCGNAM 1000 2.9 90 
EGCGINM 192 1.32 155 
EGCGINA 5.2 1.23 190 
PCACAP 4560 17.21 131 
PCAINM 192 7.74 195 
PCATPH 8.3 1.02 254 
PCANAM 1000 2.94 201 
COUNAM 1000 1.078 159 
COUINM (I) 192 1.15 172 
COUINM (II) 192 1.12 165.5 
COUCAF 22 0.314 184 
COUTHP 8 1.157 223 
COUTHB.H2O 0.5 0.294 228 
COUURE 1200 1.52 123.5 
COUINZ 12.5 1.096 178 
COUTHB 0.5 0.2812 228 
CFAINM 192 1.9415 151 
CFAGAH 142 1.2613 221 
CFAINZ 12.5 1.0616 185 
GALINM 192 2.4 202 
GALTBR 0.5 0.5 271 
GALNAC 17 8 211 
GALGAH 142 4.7 260 
FERINM 192 1.8 152 
FERNAM 1000 1.4 126 
FERTBR 0.5 0.6 192 
CAFCYA 2.7 9.69 228 
CAFELA 0.0038 0.07 300 
CAFCOU 0.789 1.1 178 
CAFFER 0.6 2.85 146 
CAFSAL 2 3.5 146 
CAF1HY 0.5 0.19 190 
CAFETG 4 0.54 144 
CAFCGA 25 11.9 131 
CAFGAL 11 5.7 244 
CAFCFA 0.485 0.671 199 
CAFSYR 5.7 1.17 180 
CAFQUR 0.0026 8.55 244 
QURCAF 22 13.3 244 
BACGAL(36.9°C) 26.4 9.37 178 
BACFER(36.9°C) 1.76 1.943 154 
CCF1 denotes API. CCF2 denotes cocrystal former. 
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Figure 2-1. Significance of quadrants Q1, Q2, Q3 and Q4 in log plot of solubility 
ratios. CCF1 denotes API. CCF2 denotes cocrystal former. 
 
 Plotting the solubility ratio of cocrystal to API against the solubility ratio of 
cocrystal former to API on a logarithmic scale, any negative value implies a solubility 
ratio of less than 1. When a more soluble cocrystal former (compared to API) leads to a 
more soluble cocrystal, these data points are captured in quadrant Q1. When the 
solubility of the cocrystal decreases with a less soluble cocrystal former (compared to 
API), they are represented in quadrant Q3. Of particular concern are the data points in 
quadrants Q2 and Q4. Quadrant Q2 depicts cocrystals that reveal a decrease in aqueous 
solubility of the cocrystal despite a cocrystal former with an aqueous solubility higher 
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than that of the API. Albeit with a less soluble cocrystal former, if the solubility of the 
cocrystal records an increase, they are found in quadrant Q4. 
 
Figure 2-2. Solubility plot of in-house cocrystals. 
 
 First and foremost, without a logarithmic scale, most data points are within an 
order of magnitude. A logarithmic plot enables a spread of the individual data points. For 
the quercetin caffeine cocrystal (QUECAF), the dissolution experiment was performed 
with caffeine as the analyte of interest. Since the cocrystal is thermodynamically stable in 
water, therefore the molar concentration of both components (caffeine and quercetin) has 
to be the same to arrive at 13.3 mg/mL. Datapoints in Q1 and Q3 suggest that solubility 
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is a transferable property from the cocrystal former to the cocrystal. However, the 
presence of several data points in Q2 suggests this is not the case. 
 
Figure 2-3. Solubility plot of literature cocrystals. 
 
 The solubility plot of cocrystals from the scientific literature tells a similar story. 
While the examples of the Pfizer cancer drug succinic acid cocrystal and the 
cis-itraconazole cocrystals are encouraging, the AMG517 cocrystals undoubtedly refutes 
the notion that a more soluble cocrystal former (compared to API) translates to a more 
soluble cocrystal. Figure 2-3 reveals data points in every quadrant. Clearly, the solubility 
of the cocrystal is not predictable based on the solubility of the cocrystal former. 
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Figure 2-4. Relationship between cocrystal solubility and cocrystal former solubility 
with respect to the API. 
 
 The resultant plot in Figure 2-4 features a cluster of datapoints near the origin 
with a few notable exceptions such as QUECAF, the Pfizer cancer drug succinic acid 
cocrystal and the cis-itraconazole cocrystals. Solubility is not a transferable 
physicochemical property. No longer can one be contented with a restricted cocrystal 
former library that favours high aqueous solubility of cocrystal former to boost the 
aqueous solubility of cocrystals. Furthermore, the opportunity cost of missing the 
cocrystal with desired aqueous solubility after substantial research and development 
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efforts, is too high. That aqueous solubility is not predictable means that every cocrystal 
potentially features utility in advantageous solubility and expands the searchable space61 
of APIs but the solubility data has to be available. While a solubility-guided approach to 
cocrystal screening is not advisable, the formation of a cocrystal, using a supramolecular 
synthon approach, is more reliable by employing persistent supramolecular 
heterosynthons62-64. Although the desired aqueous solubilities of the cocrystals are not 
predictable, they are by all means achievable after due diligence. 
 As mentioned earlier in this chapter, a crystal form with high lattice energy is 
unlikely to disintegrate and dissolve in solution readily, manifested by a high melting 
point which is an easily obtainable, experimentally verifiable physical property of a 
crystalline solid. Hence solubility enhancement upon cocrystal formation should be 
accompanied by melting point depression (∆mp = CC mp – API mp) reflected in the 
melting point of the cocrystal relative to the API, i.e. ∆mp < 0 for solubility enhancement 
and vice versa. 
35 
 
 
Figure 2-5. The relationship between change in melting point (CC mp - CCF1 mp) 
and the log of solubility ratio of cocrystal and API. CCF1 denote API. 
 
 Indeed, if the inverse relationship between lattice energy and thermodynamic 
solubility upon cocrystal formation is a simple one, all data points in figure 2-5 should 
only occupy the top left and bottom right quadrants. That most of the data points in 
figure 2-5 fall in the lower half suggests that melting point depression may be a common 
phenomenon among the cocrystals discussed herein. There may be a higher probability of 
obtaining a cocrystal with a lower melting point than a higher melting point. Hence if a 
crystal form of a solid with a lower melting point is necessary without covalent 
modifications to the API, cocrystals represent viable options. 
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2.7 Conclusion 
 The “spring-and-parachute” effect has been a unique feature of pharmaceutical 
cocrystals that are not stable in an aqueous environment. As the dissolution profile of 
more cocrystal systems become publicly available, we can expect to witness more 
examples of such systems. That the “spring-and-parachute” effect features a precipitous 
plunge to a concentration level similar to that of the pure API, is not necessarily a bad 
one. Similar dissolution profiles are presented by amorphous solids since the initial boost 
in solubility (due to the metastable amorphous form) will decline once the conversion of 
the amorphous solid (into a crystalline form) commences. However, that the 
pharmaceutical cocrystal is a crystalline solid implies it possesses all the advantages that 
a crystal form has to offer. Compared to amorphous solids, crystalline solids are preferred 
from a manufacturing and regulatory perspective due to a number of factors such as 
purity, stability and reproducibility. Furthermore, formulation strategies such as the 
judicious choice of excipients can control the kinetics of the conversion process, in the 
same way that amorphous solids are stabilized by excipients. 
 Is solubility a transferable physicochemical property of a crystalline solid? The 
results presented herein suggest that this is not the case. Several cocrystals are observed 
to be less water soluble upon cocrystal formation with cocrystal formers possessing a 
favourable solubility ratio (>1) with respect to the API. 20.3% (13/64) of the data points 
in this study fall into this category. Given the lack of publicly available dissolution and 
solubility data of cocrystals, calculation of this percentage may not be statistically 
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representative. The lack of predictability of the desired physicochemical properties points 
to a need for a cocrystal former library to be exhaustive and include cocrystal formers 
with a wide range of aqueous solubilities. In the same manner that the cocrystals were 
overlooked after initial salt screens, due diligence should be taken not to miss the targeted 
cocrystals. 
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Chapter 3. Molecular Cocrystals: Crystal Forms of Ellagic Acid 
 
3.1 Preamble 
 Crystal form (cocrystals, polymorphs, salts, hydrates and solvates) diversity is and 
will continue to be a contentious issue for the pharmaceutical industry.65-66 That the 
crystal form of an API dramatically impacts its aqueous solubility (a fixed 
thermodynamic property) is illustrated by the histamine H2-receptor antagonist ranitidine 
hydrochloride and HIV protease inhibitor ritonavir. For more than a century, the 
dissolution rate of a solid has been shown to be directly dependent on its solubility,42-43 
cēterīs paribus. A century later, it remains impossible to predict the properties of a solid, 
given its molecular structure.67 If delivery and absorption of an API are limited by its 
aqueous solubility, aqueous solubility then becomes a critical parameter linking 
bioavailability and pharmacokinetics of an API. Since the majority of APIs are BCS 
Class II (low solubility and high permeability) compounds, crystal form screening, 
optimization and selection have thus received more efforts, attention and investment. 
Given that the dissolution rate, aqueous solubility and crystal form of an API are 
intricately linked, it remains a scientific challenge to understand the nature of crystal 
packing forces and their impact upon physicochemical properties of different crystal 
forms. Indeed, the selection68 of an optimal crystal form of an API is an indispensable 
part of the drug development program. 
 Developing a crystalline form of an API has other advantages. Crystallization has 
been employed routinely in the pharmaceutical industry to separate, isolate and purify 
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drug molecules to yield a high purity product with reliable reproducibility and is a 
scalable process for manufacturing purposes. Compared to amorphous solids, a stable 
crystal form is highly desirable from manufacturing, handling and regulatory 
perspectives. In addition, the recent introduction69 of pharmaceutical cocrystals has 
expanded the patentable space of an API.61 Their novelty and utility is illustrated by the 
fact that they profoundly modify the physicochemical properties of the parent API. 
Pharmaceutical cocrystals can be defined as multiple component crystals in which at least 
one component is molecular and a solid at room temperature (the pharmaceutically 
acceptable cocrystal former) and forms a supramolecular synthon with a molecular or 
ionic API. They have added another dimension to the diversity of possible crystal forms 
(traditionally restricted to polymorphs, salts, solvates and hydrates) and augmented the 
drug discovery funnel. With a myriad of possible crystal forms waiting to be discovered, 
it is not surprising that pharmaceutical scientists have resorted to high throughput 
screening (HTS) techniques to assist them in their endeavor. 
 Screening techniques such as solvent drop grinding, SonicSlurry™, HTS 
evaporation experiments, and reaction crystallization are some of the routine screening 
tools. Using carbamazepine, these four screening techniques identified a total of 27 solid 
phases with 18 carboxylic acids as cocrystal formers.70 50 piroxicam cocrystals71 were 
identified in screening experiments using 23 carboxylic acids. 18 carboxylic acids were 
combined with meloxicam to produce 19 cocrystals.72 Other examples of API carboxylic 
acid cocrystals include itraconazole,49 fluoxetine hydrochloride,36 developmental sodium 
channel blocker,73 fluconazole,74 caffeine,75 theophylline,75 gabapentin,76 AMG517,52 
minoxidil77 and ethenzamide.55, 78-79 Many carboxylic acids are included in a Generally 
40 
 
Recognised As Safe80 (GRAS) list and are thus routinely engaged as pharmaceutically 
acceptable cocrystal formers. However, pharmaceutically acceptable cocrystal formers 
must go beyond carboxylic acids to truly diversify the crystal forms available to APIs. 
For instance, polyphenols possess potent hydrogen bonding functional groups capable of 
molecular recognition. Furthermore, they are present in our diet81 in the fruits, tea82 and 
wine83 that are commonly consumed and often exhibit pharmacological properties as 
well. Obviously, they have to be pharmaceutically acceptable even though the 
toxicology84 profile may not be thoroughly investigated. Indeed, this has been 
demonstrated with pterostilbene as a cocrystal former to prepare cocrystals with caffeine 
and carbamazepine.60 
 
Figure 3-1. The phenol-carbonyl supramolecular heterosynthon is featured in the 
cocrystals of (caffeine)•(pterostilbene) (left) and (carbamazepine)•(pterostilbene) 
(right). 
 
 Ellagic acid85 is a naturally occurring polyphenolic nutraceutical86-87 derived from 
the hydrolysis of ellagitannins88 and it is abundant in pomegranates and raspberries. 
According to DeFelice, a nutraceutical is defined as “a food (or part of a food) that 
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provides medical or health benefits, including the prevention and/or treatment of a 
disease. It has been widely studied for its pharmacological properties.89-90 However, it is 
reported to possess an aqueous solubility of only 3.8 μg/ml91 at 25°C. This has restricted 
recent nutritional research to focus on the pharmacokinetics of pomegranate juice/extract 
rather than pure ellagic acid in healthy subjects,92-96 since its poor aqueous solubility 
limits bioavailability. In two separate pharmacokinetic studies administrating 
pomegranate extract and pomegranate juice in healthy human subjects, ellagic acid was 
detected in human plasma with a maximum concentration (Cmax) of about 33 ng/mL97-98 
at a time of maximum concentration (Tmax) of 1 hour after ingestion. The poor aqueous 
solubility of ellagic acid has impeded its potential as a therapeutic molecule. There is a 
need to improve the aqueous solubility of ellagic acid from a clinical perspective. 
Although a number of pharmacokinetic studies have been focused on ellagic acid, little 
information on its solid state chemistry has been reported in the open literature. That 
ellagic acid possesses extremely low aqueous solubility makes it a worthy candidate for 
cocrystal formation since aqueous solubility is a critical physicochemical property that 
can decide the fate of an API. 
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Table 3-1. Molecular Structures of Ellagic Acid and Group 1 Basic Cocrystal 
Formers with their three letter code. 
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Table 3-2. Group 2 Zwitterionic Cocrystal Formers with their three letter code. 
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Table 3-3. Group 3 Neutral Cocrystal Formers with their three letter code. 
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Table 3-4. Solvates of Ellagic Acid. 
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 With this in mind, we explore the crystal form landscape of ellagic acid. 
Amenable to crystal engineering design principles, ellagic acid has an imbalance of 
hydrogen bond donors over acceptors, which suggests that perhaps it may be prone 
towards cocrystal formation and/or solvation by molecules with superior hydrogen bond 
acceptor capabilities. Its molecular planarity and rigidity also makes it an attractive 
crystal engineering target. To date, three crystal structures of ellagic acid (anhydrate, 
dihydrate and tetrakis(pyridine) solvate) were reported in the Cambridge Structural 
Database99 (CSD). Cocrystals of ellagic acid had addressed supramolecular 
heterosynthons64 (between phenols and carboxylates) and structure-stability 
relationships100 (thermal stability of cocrystal hydrates). A grouped library of successful 
cocrystal formers include (1) nicotinamide, isonicotinamide, caffeine, theophylline, 3,5-
dimethylpyrazole, (2) sarcosine, N,N-dimethylglycine, (3) ε-caprolactam and urea. Group 
1 involves cocrystal formers with basic pyridine, imidazole and pyrazole moieties. Group 
2 contains zwitterionic cocrystal formers having negatively-charged carboxylate 
moieties. Group 3 features the neutral carbonyl group. Other crystal forms of ellagic acid 
include solvates from N,N-dimethylacetamide (DMA), N-Methyl-2-pyrrolidone (NMP), 
dimethylsulfoxide (DMSO) and (±)propylene glycol (PG). Although the discovery of 
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solvates was serendipitous, the supramolecular synthons observed in these structures 
nevertheless render themselves useful in the design of cocrystals. 
 
3.1.1 CSD Survey of Ellagic Acid 
 
Figure 3-2. Crystal forms of ellagic acid: anhydrate (top left), dihydrate (top right) 
and tetrakis(pyridine) solvate (bottom). 
 
 Analysis of existing crystal structures represents the first step in a crystal 
engineering experiment.101 A survey of the CSD for crystal forms of ellagic acid returned 
three hits, an anhydrate101 (Refcode: ELLAGC), a dihydrate102 (KUVBEI) and 
tetrakis(pyridine) solvate103 (VASYEU). In the crystal structure of anhydrous ellagic 
acid, ellagic acid molecules are arranged into a chain by phenol-phenol supramolecular 
homosynthon. Adjacent chains are cross-linked by phenol-carbonyl supramolecular 
ELLAGC KUVBEI 
VASYEU 
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heterosynthon to generate a flat sheet. Adjacent sheets are π-stacked to complete the 
crystal packing. In the dihydrate, water molecules insert themselves between ellagic acid 
molecules so that the chains are sustained by OH•••O(water) interactions. Adjacent 
chains are linked by OH•••O(water)  and OH(water)•••O=C interactions. Similarly, 
adjacent sheets are reinforced by π-stacking104 interactions. The crystal structure of the 
tetrakis(pyridine) solvate of ellagic acid reveals a discrete supermolecule105 assembled 
from one ellagic acid molecule and four pyridine solvent molecules linked via phenol-
pyridine supramolecular heterosynthon. The presence of the tetrakis(pyridine) solvate 
suggests the phenol-pyridine supramolecular heterosynthon is more robust than the 
phenol-phenol supramolecular homosynthon and should be exploited for cocrystal 
formation. 
 
3.1.2 Cocrystals of Polyphenols with Group 1 Basic Cocrystal Formers (Pyridine, 
Imidazole, Pyrazole) 
 The supramolecular heterosynthons responsible for the formation of cocrystals 
between phenols and pyridine/imidazole/pyrazole has been documented. The dominant 
phenol-pyridine supramolecular heterosynthon has been employed by the groups of 
MacGillivray, Nangia and Zaworotko in constructing cocrystals of polyphenols. 
MacGillivray106 et al. used resorcinol as a template to align trans-1,2-bis(4-
pyridyl)ethylene into a photoreactive supermolecule for the [2+2] photodimerization of 
trans-1,2-bis(4-pyridyl)ethylene (which is otherwise photostable) to yield rctt-tetrakis(4-
pyridyl)cyclobutane. 
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Figure 3-3. The phenol-pyridine supramolecular heterosynthon aligns two olefins 
into a discrete photoreactive supermolecule105 (top). A projection of the discrete 
photoproduct on the ac plane (bottom). 
 
 Peddy et al. prepared a series of cocrystals of phenols with isonicotinamide107 that 
exhibit the phenol-pyridine supramolecular heterosynthon. To demonstrate the preference 
of phenols for pyridines over cyano groups in a competitive hydrogen bonding 
environment,  Bis et al. prepared and characterized a series of cocrystals with persistent 
phenol-pyridine supramolecular heterosynthon63 in the presence of cyano groups. That 
the phenol-pyridine supramolecular heterosynthon is superior to the phenol-cyano 
supramolecular heterosynthon is confirmed when mixtures of starting materials were 
obtained from experiments to obtain cocrystals of 3-hydroxypyridine or 5-
hydroxyisoquinoline with cyano derivatives. 
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Figure 3-4. A chain of alternating caffeine molecules and methyl gallate molecules in 
(caffeine)·(methyl gallate) cocrystal (top), alternating pairs of methyl gallate and 
theophylline dimer forms a flat sheet in the (theophylline)·(methyl gallate) cocrystal 
(bottom). 
 
 Substituted xanthines (such as caffeine and theophylline) are biologically active 
molecules that feature basic imidazoles, and are potent corystal formers for acidic 
molecules.  Trask et al. reported a series of cocrystals with caffeine108 and theophylline109 
using a homologous series of dicarboxylic acids (oxalic acid, malonic acid, maleic acid, 
succinic acid110 and glutaric acid). Coincidently, both caffeine/theophylline oxalic acid 
cocrystals were stable to hydration at 98% RH for a period of seven weeks, confirmed by 
powder X-ray diffraction. Weakly acidic phenols are equally adept in interacting with 
substituted xanthines111, demonstrated by their methyl gallate cocrystals.40, 112 The crystal 
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packing of the cocrystal helps to improve the mechanical properties compared to caffeine 
due to the introduction of a slip system. The ability of pyrazoles to form cocrystals with 
polyphenols was illustrated through 3,5-dimethypyrazole and phloroglucinol.113 
 
3.1.3 Cocrystals of Polyphenols with Group 2 Zwitterionic Cocrystal Formers 
 Zwitterions such as the proteinogenic amino acids are perhaps the best cocrystal 
formers in terms of their toxicology profile, cost and ready availability. In general, a 
zwitterion is a dipolar ion that carries both a positive and negative charge114 and has a 
total net charge of zero.115 They had been used in the resolution of optical isomers 
involving cocrystals of homochiral mandelic acid. (S)-alanine116 and (R)-cysteine117 can 
be used to resolve racemic mandelic acid. (S)-mandelic acid is able to resolve racemic 2-
aminobutyric acid and phenylalanine through fractional crystallization. Importantly, (S)-
mandelic acid is used to resolve racemic pregabalin118 (active ingredient in LYRICA® 
that is used to treat neuropathic pain) on an industrial scale. Examples of zwitterionic 
cocrystals exist in the CSD.119-127 The utility of carboxylates in cocrystal formation has 
expanded the scope of zwitterionic cocrystals beyond carboxylic acids to include 
molecules with weakly acidic hydroxyl moieties100, as exemplified by polyphenols and L-
ascorbic acid. 
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Figure 3-5. A 1:1 cocrystal of L-ascorbic acid and sarcosine sustained by 
carboxylate-hydroxyl supramolecular heterosynthon. 
 
3.1.4 Cocrystals of Polyphenols with Group 3 Neutral Cocrystal Formers 
(Carbonyl) 
 
Figure 3-6. ε-caprolactam molecules exist as dimers and bridge resorcinol 
molecules. 
 
 The carbonyl group is a component of many organic functional groups such as the 
carboxylic acid, primary, secondary and tertiary amides, aldehyde, ketone, ester, lactone 
and lactam. While the supramolecular chemistry of carboxylic acids, primary and 
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secondary amides have been explored, the same cannot be said of the other functional 
groups. Using ε-caprolactam and urea, we probe the propensity of the carbonyl group to 
engage in hydrogen bonding interaction with polyphenols. Urea is a small organic 
molecule that is prone to forming urea inclusion128-129 compounds. Supramolecular 
heterocatemers130 have been constructed from polyphenols (such as 4,4’-biphenol and 
resorcinol) and ε-caprolactam to highlight their role in cocrystal design. 
 
 
3.2 Results and Discussion 
 Cocrystals, cocrystal solvates/hydrates and solvates of ellagic acid were prepared 
and fully characterized. The synthesis of these cocrystals demonstrated the utility of 
polyphenols as cocrystal formers for a wide variety of functional groups, such as, 
pyridine, imidazole, pyrazole, zwitterions and carbonyl groups. 
 
3.2.1 Crystal Forms of Ellagic Acid with Group 1 Basic Cocrystal Formers 
(Pyridine, Imidazole, Pyrazole) 
 ELANAM: The crystal structure of ELANAM reveals it is a 1:2 cocrystal of 
ellagic acid and nicotinamide. ELANAM exhibits hydrogen bonding between the pyridyl 
group of nicotinamide and the phenolic moieties of ellagic acid [OH•••N: 2.630(5) Å]. 
The neutral nature of nicotinamide is supported by the C-N-C angle of 116.35° in the 
pyridyl group. Two nicotinamide molecules adopt the amide dimer. The phenol-pyridine 
supramolecular heterosynthon63, 107, 131 and the amide dimer supramolecular 
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homosynthon132-134 [NH•••O:  3.040(7) Å] generate an undulating tape. Two ellagic acid 
molecules sandwich the amide dimer with the carbonyl and phenolic moieties to form a 
ܴଷଷ(10) trimer [OH•••O: 2.694(6) Å and NH•••O: 2.953(7) Å]. The trimeric interaction 
(figure 2-6) links the undulating tapes together to yield the overall crystal packing. 
 
Figure 3-7. The undulating ELANAM tapes are crosslinked by sandwiching the 
amide dimer with a pair of ellagic acid molecules. 
 
 ELAINM: Three crystal forms of ELAINM were obtained: a variable hydrate, a 
NMP solvate and DMA solvate. 
 Crystal structure analysis of ELAINM•1.7H2O reveals one ellagic acid molecule, 
two isonicotinamide molecules and disordered water molecules in the unit cell. 
ELAINM•1.7H2O exhibits hydrogen bonding between the pyridyl group of 
isonicotinamide and the phenolic moieties of ellagic acid [OH•••N:  2.611(2) Å]. The 
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neutral nature of isonicotinamide is supported by the C-N-C angle of 118.07° in the 
pyridyl moiety.  Two isonicotinamide molecules exist as dimers through amide dimer 
supramolecular homosynthons [NH•••O:  2.988(3) Å]. The phenol-pyridine 
supramolecular heterosynthon and the amide dimer supramolecular homosynthon 
generate a tape (figure 2-7). The amide dimer also acts as both a hydrogen bond donor 
and acceptor towards the carbonyl [NH•••O: 2.930(3) Å] and phenolic moieties of ellagic 
acid [OH•••O:  2.749(2) Å] to form a ܴଷଷ(10) trimer that links adjacent chains. Disordered 
water molecules occupy channels parallel to the crystallographic a axis. 
 
Figure 3-8. Crystal packing of ELAINM·1.7H2O reveals isonicotinamide dimers 
with lateral hydrogen bonding to phenolic and carbonyl moieties of ellagic acid. 
Water molecules (shown as large vdw spheres) occupy channels parallel to the 
crystallographic a axis. 
 
 The crystal structure of ELAINM•4NMP reveals it is a tetrakis(NMP) solvate of 
the 1:2 cocrystal of ellagic acid and isonicotinamide. Isonicotinamide molecules exist as 
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dimers via the amide dimer supramolecular homosynthon [NH•••O: 2.923(4) Å]. The 
pyridyl group interacts with the phenolic moiety [OH•••N distance of 2.647(4) Å] to form 
a linear chain. The crystal structure is sustained by the phenol-pyridine and amide-amide 
supramolecular synthons. Along the periphery of the chain, four NMP molecules are 
positioned to engage the two remaining hydrogen bond donors (from ellagic acid) via 
phenol-carbonyl supramolecular heterosynthon [OH•••O: 2.615(4) Å], and another two 
dangling N-H donors [from the amide dimer, NH•••O: 2.827(5) Å]. 
 
Figure 3-9. The supramolecular tape in ELAINM has excess hydrogen bond donors 
from phenolic moieties of ellagic acid and amide dimer of isonicotinamide, 
attracting the NMP solvent molecules (top) and DMA solvent molecules (bottom). 
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 The crystal structure of ELAINM•4DMA reveals a 1:2:4 ellagic acid, 
isonicotinamide and DMA cocrystal solvate in which two of the four DMA molecules are 
crystallographically disordered. ELAINM•4DMA is isostructural with ELAINM•4NMP. 
Isonicotinamide molecules are dimers via the amide dimer supramolecular homosynthon 
[NH•••O: 2.895(3) Å]. The pyridyl group interacts with the phenolic moiety [OH•••N: 
2.647(3) Å] to form a linear chain. Along the periphery of the chain, four DMA 
molecules are positioned to engage the two remaining hydrogen bond donors (from 
ellagic acid) via phenol-carbonyl supramolecular heterosynthon [OH•••O: 2.608(3) Å], 
and another two dangling N-H donors [from the amide dimer, NH•••O: 2.792(7) Å]. 
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Figure 3-10. Crystal Packing in ELACAF·H2O reveals hydrogen bonding between 
ELA and CAF molecules (top). Water molecules reinforce the hydrogen bonding 
interaction between adjacent sheets (bottom). 
 
 ELACAF•H2O: Analysis of the crystal structure reveals that ELACAF•H2O 
contains two ellagic acid molecules, two caffeine molecules and two water molecules in 
the unit cell. The phenolic moieties of ellagic acid act as hydrogen bond donors to the 
basic imidazole [OH•••N: 2.702(4) Å] and carbonyl moieties of caffeine molecules 
[OH•••O: 2.708(3) Å] so as to form straight chains of alternating ellagic acid and caffeine 
molecules. Adjacent chains are linked via OH(ELA)•••O=C(CAF) hydrogen bonds 
[2.708(3) Å] and water molecules [2.608(3) Å and 2.854(4) Å] that hydrogen bond to two 
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ELA molecules, thereby forming a sheet [Figure 3-10(top)]. Adjacent sheets are 
crosslinked by hydrogen bonds between water molecules and carbonyl oxygen atoms of 
ellagic acid [2.920(4) Å]. The water molecules are in isolated environments. 
 ELATPH: Two crystal forms of ELATPH were obtained: a partial hydrate and a 
DMA solvate. 
 
Figure 3-11. A projection of ELATPH·0.13H2O on the ac plane (top), a chain is 
constructed in ELATPH·2DMA (bottom). 
 
 The X-ray structure of ELATPH•0.13H2O reveals a 1:2 cocrystal of ellagic acid 
and theophylline. Theophylline molecules exist as ܴଶଶ(10) dimers [N-H•••O:  2.714(2) Å], 
allowing the remaining carbonyls from the dimer to engage the phenolic moieties of 
ellagic acid [OH•••O: 2.757(2) Å] to form a straight chain. This straight chain is 
crosslinked at an angle with adjacent straight chains via phenol-imidazole supramolecular 
heterosynthon [N-H•••O: 2.711(2) Å] to generate stacks of crosses. Traces of water are 
present in the X-ray crystal structure represented by the isolated red spheres in figure 
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3-11(top). The water molecules hydrogen bond with the carbonyls [OH•••O: 2.611 Å] of 
ellagic acid and theophylline [OH•••O: 2.785Å]. 
 In ELATPH•2DMA, theophylline molecules exist as dimers [N-H•••O: 
2.804(3) Å], allowing the imidazole nitrogen of theophylline to interact with the phenolic 
moieties [OH•••N: 2.849(3) Å] and establish a linear chain. Similarly, the crystal 
structure is sustained by the phenol-imidazole supramolecular heterosynthon and the 
theophylline dimer. Two disordered DMA molecules are located along the periphery of 
the chain to satisfy the two remaining hydrogen bond donors (from ellagic acid) via 
phenol-carbonyl supramolecular heterosynthon [OH•••O: 2.548(4) Å]. 
 
Figure 3-12. A discrete assembly is established in ELADMP. 
 
 ELADMP: X-ray structural analysis reveals a 1:2 cocrystal of ellagic acid and 
3,5-dimethylpyrazole. Centrosymmetric 3,5-dimethylpyrazole molecules sandwich an 
ellagic acid molecule via OH(phenol)•••N(pyrazole) interaction [OH•••N: 2.588(4) Å] 
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and NH(pyrazole) •••O=C(lactone) interaction [NH•••O: 2.973(4) Å] to form a 
supermolecule. The remaining phenolic moieties engage in T-shaped OH•••π [OH•••π: 
3.263(5) Å] interactions135 with adjacent 3,5-dimethylpyrazole molecules to generate a 
herringbone arrangement. 
 
3.2.2 Crystal Forms of Ellagic Acid with Group 2 Zwitterionic Cocrystal Formers 
 ELASAR: The crystal structure of ELASAR reveals that the 1:1 cocrystal of 
ellagic acid and sarcosine is sustained by charge-assisted O-H•••O supramolecular 
heterosynthon [2.594(2) Å and 2.630(2) Å] to form ܴସସ(18) tetramers [figure 3-13(top)]. 
Each carboxylate moiety of sarcosine interacts with four ellagic acid molecules whereas 
each ammonium moiety forms a charge-assisted N-H•••O supramolecular heterosynthon 
[2.905(3) and 3.025(3) Å] with the phenolic moieties of two ellagic acid molecules. The 
ellagic acid molecules are π-stacked in a slipped orientation [figure 3-13 (bottom)]. 
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Figure 3-13. The phenol-carboxylate supramolecular heterosynthon (top), π-
stacking interactions in the crystal packing of ELASAR (bottom) 
 
 ELADMG: The 1:1 cocrystal of ellagic acid and N,N-dimethylgycine also 
exhibits the ܴସସ(18) tetramer [OH•••O: 2.649(1) Å and 2.903(2) Å] [figure 3-14(left)]. 
The ammonium moiety of N,N-dimethylglycine interacts with one phenolic moiety 
[NH•••O: 2.887(2) Å] whereas the ellagic acid molecules are π-stacked in a staggered 
orientation [figure 3-14(right)]. 
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Figure 3-14. The phenol-carboxylate supramolecular heterosynthon (left), π-
stacking interactions reinforce the crystal packing forces in ELADMG (right) 
 
3.2.3 Crystal Forms of Ellagic Acid with Group 3 Neutral Cocrystal Formers 
(Carbonyl) 
 ELACAP: The X-ray crystal structure reveals it is a 1:2 cocrystal of ellagic acid 
and ε-caprolactam. The phenolic moieties act as hydrogen bond donors towards the 
carbonyls of ε-caprolactam [OH•••O: 2.696(9) Å and 2.724(9) Å]. The carbonyl groups 
of ellagic acid act as hydrogen bond acceptors towards the NH of ε-caprolactam 
[NH•••O: 2.903(10) Å]. The two supramolecular heterosynthons generate a 3-periodic 
network of supramolecular heterocatemers. 
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Figure 3-15. A supramolecular heterocatemer is assembled in ELACAP. 
 
 ELAURE•2NMP: Analysis of the crystal structure reveals a bis(NMP) solvate of 
a 1:2 cocrystal of ellagic acid and urea. The phenol-carbonyl supramolecular 
heterosynthon is prevalent with all phenolic moieties interacting with the carbonyl of two 
crystallographically independent urea [OH•••O: 2.543(5) Å and 2.684(4) Å] and NMP 
molecules [OH•••O: 2.581(4) Å and 2.657(5) Å]. Centrosymmetric urea dimers [NH•••O: 
2.899(6) Å] bridge four ellagic acid molecules [NH•••O: 2.983(5) Å and 3.058(5) Å] 
from different staggered layers. Channels are generated along the crystallographic a axis 
to accommodate chains of hydrogen bonded urea molecules [NH•••O: 2.922(5) Å and 
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2.959(6) Å]. NMP molecules are present to interact with the remaining hydrogen bond 
donors from ellagic acid. 
 
Figure 3-16. A chain of hydrogen bonded urea molecules occupy channels down the 
crystallographic a axis in the crystal packing of ELAURE·2NMP. 
  
3.2.4 Solvates of Ellagic Acid 
 Additional crystal forms of ellagic acid were obtained in the form of solvates 
using DMA, NMP, DMSO and (±)-PG. The crystal packing of some of these solvates 
resembles that of the dihydrate and tetrakis(pyridine) solvate of ellagic acid. 
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Figure 3-17. The similarity in crystal packing between the ELADMA4 solvate and 
the tetrakis(pyridine) solvate (inset). 
 
 ELADMA4: The tetrakis(DMA) solvate is sustained by phenol-carbonyl 
supramolecular heterosynthon between the phenolic moieties of one ellagic acid molecule 
with four DMA molecules [OH•••O: 2.6148(16) Å  and 2.5770(16) Å]. This crystal 
structure resembles that of the tetrakis(pyridine) solvate (Refcode: VASYEU) with 
slightly further hydrogen bonding distances [OH•••N: 2.622(3) Å and 2.795(4) Å] 
compared to the tetrakis(DMA) solvate. A discrete assembly is formed and the overall 
crystal packing is a herringbone arrangement. 
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Figure 3-18. The similarity in crystal packing between the ELADMA2 solvate and 
the dihydrate (inset). 
 
 ELADMA2: The bis(DMA) solvate of ellagic acid is sustained by phenol-
carbonyl supramolecular heterosynthon, with the phenolic moieties of two adjacent 
ellagic acid molecules bridged by two DMA molecules to form a ܴସଶ(14) tetramer 
[OH•••O: 2.6696(14) Å and 2.8393(14) Å]. This unit propagates into a linear chain and 
resembles the crystal packing of ellagic acid dihydrate (Refcode: KUVBEI). In the 
crystal structure of ellagic acid dihydrate, the crystal packing forces were maximized 
with water molecules bridging adjacent chains via OH(water)•••O=C(lactone) interaction, 
reinforced by π-stacking interaction. The same is not possible for this DMA solvate since 
DMA does not possess labile protons available for hydrogen bonding and the 
comparatively bigger DMA molecules (relative to H2O molecules) caused adjacent 
chains to be displaced such that π-stacking interactions cannot be made efficiently. 
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Figure 3-19. DMSO molecules tether ELA molecules into a straight chain. 
 
 ELADMSO2: The bis(DMSO) solvate is sustained by phenol-sulfoxide 
supramolecular heterosynthon [OH•••O=S: 2.674(3) Å and 2.695(3) Å]. Two adjacent 
ellagic acid molecules are tethered by two bridging DMSO molecules to form a ܴସଶ(14) 
tetramer. This unit propagates linearly into a chain and the crystal packing resembles that 
of both the bis(DMA) solvate and ellagic acid dihydrate. Here, π-stacking interactions 
reinforced the crystal packing forces. 
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Figure 3-20. A projection of ELANMP2 on the ac plane. 
 
 ELANMP2: The bis(NMP) solvate is sustained by phenol-carbonyl 
supramolecular heterosynthon where the phenolic moieties of two ellagic acid molecules 
are bridged by one NMP molecule [OH•••O: 2.697(4) Å and 2.745(4) Å]. Unlike the 
bis(DMA) solvate and bis(DMSO) solvate, the phenolic moieties do not hydrogen bond 
in a concerted manner to the same two NMP molecules to avoid the formation of another 
chain structure. Instead, the NMP molecules are bridging ellagic acid molecules to 
generate a supramolecular heterocatemer packed in a herringbone arrangement. 
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Figure 3-21. (±)PG molecules align the ellagic acid molecules. 
 
 ELAPG2: The bis(±)PG solvate is sustained by OH(phenol)•••OH(aliphatic 
alcohol) and OH(aliphatic alcohol)•••O=C(lactone) interactions at 2.660(3) Å and 
2.734(3) Å respectively. PG molecules of opposite chirality bridge adjacent ellagic acid 
molecules into π-stacks, with the shortest distance of two ellagic acid planes at 3.280 Å. 
  
3.3 Conclusion 
 17 crystal forms (5 cocrystals, 7 cocrystal solvates/hydrates and 5 solvates) of 
ellagic acid have been presented herein. It seems ellagic acid is particularly prone to 
solvation. Although they are usually discovered serendipitously, the supramolecular 
synthons observed in these structures can still render themselves useful in the design of 
cocrystals. Unlike calixarenes136 and cyclodextrins137 that act as hosts to accommodate 
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guest molecules in their cavities, ellagic acid does not possess any molecular feature to 
suggest a tendency towards small molecule uptake such as solvent molecules. The 
solvated/hydrated crystal structures reveal they are neither inclusion compounds, i.e. the 
crystal packing does not generate pockets of empty spaces to trap molecules of 
appropriate volume. As mentioned at the start of this chapter, the imbalance of hydrogen 
bond donors over acceptors implies that given the opportunity, ellagic acid will prefer to 
accommodate a hydrogen bond acceptor in its local environment to satisfy its hydrogen 
bonding requirements. Furthermore, the lactone functional group is not known to be a 
target in crystal engineering studies, i.e., a stronger hydrogen bond acceptor will engage 
in hydrogen bonding interaction with the phenolic moieties. Hence, it is not surprising 
that the phenol-carbonyl(lactone) interaction is only observed in the crystal structure of 
anhydrous ellagic acid. However, in the presence of molecules with superior hydrogen 
bonding acceptor capabilities, the phenolic moieties participate in hydrogen bonding 
readily, disrupting the crystal packing of anhydrous ellagic acid. The crystal structures of 
the five cocrystal solvates/hydrates are a further testament of this imbalance of hydrogen 
bond donors over acceptors. Referring to the isonicotinamide and theophylline cocrystal 
solvates, there remains an excess of hydrogen bond donors after the formation of the 
phenol-pyridine supramolecular heterosynthon and the phenol-imidazole supramolecular 
heterosynthon. Hence the solvent molecules are included in the crystal lattice around the 
periphery of the established unit. 
 Examination of the crystal form landscape of ellagic acid has demonstrated that it 
has a preference for molecules capable of hydrogen bond acceptor properties in its local 
environment. Pyridines, imidazoles, pyrazole, zwitterions and carbonyl groups have been 
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manipulated to yield the cocrystals. The results presented herein further our 
understanding of the supramolecular chemistry of polyphenols, confirm the feasibility of 
polyphenols to serve as cocrystal formers for a diverse variety of functional groups and 
demonstrate the phenol-carbonyl supramolecular heterosynthon to be reliable and useful 
in a predictable manner. The crystal structure of anhydrous ellagic acid reveals linear 
chains of ellagic acid molecules (established by forming a catechol dimer), crosslinked 
via OH···O=C(lactone) interaction and reinforced by π-stacking interactions. The DMA 
and NMP solvates of ellagic acid suggest that tertiary amides are perhaps better hydrogen 
bond acceptors than lactones. The crystal structures of the cocrystal solvates highlight the 
synergistic cooperation exhibited among the phenol-pyridine supramolecular 
heterosynthon, phenol-imidazole supramolecular heterosynthon and the phenol-carbonyl 
supramolecular heterosynthon. That the solvents are included in the crystal lattice, 
despite the phenol-pyridine supramolecular heterosynthon and phenol-imidazole 
supramolecular heterosynthon playing a critical role in the self-assembly of the cocrystal 
solvates, implies that the phenol-carbonyl supramolecular heterosynthon is robust, 
especially when there is an excess of hydrogen bond donors such as in the presence of a 
polyphenol. The synergism demonstrated between the phenol-pyridine supramolecular 
heterosynthon and phenol-imidazole supramolecular heterosynthon with the phenol-
carbonyl supramolecular heterosynthon (in the cocrystal solvates) suggests the possibility 
of a ternary cocrystal and adds another level of complexity to the possible structures that 
can be constructed. 
 In conclusion, the crystal forms (cocrystals, cocrystal solvates/hydrates and 
solvates) of ellagic acid are achieved by a variety of supramolecular heterosynthons 
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formed between polyphenols with pyridines, imidazoles, pyrazole, carboxylates and 
carbonyl moieties. The propensity of polyphenolic molecules to engage in molecular 
recognition events, leading to the formation of supramolecular heterosynthons, has been 
the subject of intense scrutiny. The delineation of supramolecular synthons into a 
hierarchy has undoubtedly unleashed the power of the supramolecular heterosynthon 
approach to the crystal engineering of cocrystals. The synergism exhibited among 
supramolecular heterosynthons is a coveted attribute in a hydrogen bonding cooperative 
environment. That APIs routinely contain multiple functional groups enables polyphenols 
to play a role as cocrystal formers in the crystal form screening of APIs. This information 
is relevant to the pharmaceutical, food and nutrition industry in their crystal form 
screening since polyphenols are found in a variety of food sources (tea, wine, fruits) with 
known toxicology profile. Indeed, the range of pharmaceutically acceptable cocrystal 
formers available for crystal form screening would be considerably broadened if 
polyphenols were to be included in cocrystal former libraries. 
 
3.4 Materials and Methods 
 Ellagic acid dihydrate was purchased from TCI America (Lot. 6LHXG) and used 
as received. Ellagic acid dihydrate from other suppliers may not reproduce these results if 
they are not easily soluble in pyridine, DMA and NMP. 
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3.4.1 Synthesis of Crystal Forms of Ellagic Acid 
 ELANAM: Ellagic acid dihydrate (20.0 mg, 0.06 mmol) was dissolved in 0.5 mL 
of NMP with heat. Nicotinamide (144.0 mg, 11.8 mmol) was dissolved in 0.5 mL of 
deionised water with heat. The contents were mixed and left for slow evaporation. 
Yellow plate-like crystals (15.6 mg, 288°C) were harvested after a week. 
 ELAINM•1.7H2O: Ellagic acid dihydrate (20.0 mg, 0.06 mmol) was dissolved in 
2 mL of DMA. Isonicotinamide (290 mg, 2.37 mmol) was dissolved in 1 mL of deionised 
water. Both contents were mixed to give a light brown solution and left for slow 
evaporation. Yellow plate-like crystals (18.1 mg, mp 300°C) were harvested after one 
month. 
 ELAINM•4NMP: Ellagic acid dihydrate (20.0 mg, 0.06 mmol) and 
isonicotinamide (80.0 mg, 0.66 mmol) were dissolved in 1 mL of NMP with heat. The 
yellow solution was left for slow evaporation. Yellow crystals (16.6 mg, 290°C) were 
harvested overnight. 
 ELACAF•H2O: Ellagic acid dihydrate (10.0 mg, 0.03 mmol) and caffeine 
(29.0 mg, 2.37 mmol) were added to 5 mL of (±)1,2-propanediol/ethanol (6:4 volume 
ratio) and heated on a hotplate until boiling occurred. The contents were cooled to room 
temperature and filtered to obtain a yellow solution. The solution was left to stand. 
Yellow oval plate-like crystals (3.9 mg, mp, 300°C) were harvested after a week.  
 ELATPH•0.13H2O: Ellagic acid dihydrate (10.0 mg, 0.03 mmol) and anhydrous 
theophylline (27.0 mg, 0.15 mmol) were added to 5 mL of ethanol with heat until boiling 
72 
 
occurred. The contents were cooled to room temperature and filtered to obtain a yellow 
solution. The solution was left for slow evaporation. Yellow plate-like crystals (11.1 mg, 
326°C) were harvested the next day. 
 ELATPH•2DMA: Ellagic acid dihydrate (50.0 mg, 0.15 mmol) and and 
anhydrous theophylline (134.0 mg, 0.75 mmol) were dissolved in 2 mL of DMA with 
heat. The solution was left for slow evaporation. Yellow plate-like crystals (63.7 mg, 
326°C) were harvested after a week. 
 ELADMP: Ellagic acid dihydrate (5.0 mg, 0.015 mmol) was dissolved in 5 mL of 
hot (±)PG. 3,5-dimethylpyrazole (143.0 mg, 15 mmol) were added. The solution was left 
for slow evaporation. Yellow needle-like crystals (2.9 mg, 237°C) were harvested after 
one month. 
 ELASAR: Ellagic acid dihydrate (10.0 mg, 0.03 mmol) was dissolved in 5 mL of 
hot methanol. Sarcosine (10.0 mg, 0.11 mmol) was dissolved in 5 mL of hot methanol. 
Both contents were mixed to give a yellow solution and left for slow evaporation. Yellow 
plate-like crystals (6.5 mg, 320oC) were harvested after two days. 
 ELADMG: Ellagic acid dihydrate (10.0 mg, 0.03 mmol) was dissolved in 5 mL of 
hot methanol. N,N-dimethylglycine (10.0 mg, 0.11 mmol) was dissolved in 5 mL of hot 
methanol. Both contents were mixed to give a yellow solution and left for slow 
evaporation. Yellow plate-like crystals (5.6 mg, 293°C) were harvested after two days. 
 ELACAP: Ellagic acid dihydrate (10.0 mg, 0.03 mmol) and ε-caprolactam 
(268.0 mg, 2.37 mmol) were added to 5 mL of isopropanol with heat. The content was 
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filtered to obtain a yellow solution. It was allowed to slowly evaporate at room 
temperature. Yellow triangular plate-like crystals (6.2 mg, 276°C) were harvested after a 
month. 
 ELAURE•2NMP: Ellagic acid dihydrate (10.0 mg, 0.03 mmol) and urea 
(27.0 mg, 0.45 mmol) were dissolved in 2 mL NMP/H2O (1:1 volume ratio) with heat. 
The solution was left to stand in air. Yellow block crystals (9.3 mg, 200°C) were 
harvested after a week. 
 ELADMA4: Ellagic acid dihydrate (50.0 mg, 0.15 mmol) was dissolved in 1 mL 
of DMA. The brown solution was left for slow evaporation. Colourless block crystals 
(45.0 mg) were harvested after a week. 
 ELADMA2: Ellagic acid dihydrate (20.0 mg, 0.06 mmol) and oxalic acid 
(107.0 mg, 1.18 mmol) was dissolved in 1 mL of DMA with heat. The brown solution 
was left to stand in air. Yellow block crystals (10.2 mg) were harvested after a week. 
 ELADMSO2: Ellagic acid dihydrate (10.0 mg, 0.03 mmol) was dissolved in 1 mL 
of DMSO with heat. The brown solution was left for slow evaporation. Yellow plate-like 
crystals (9.9 mg) were harvested after three days. 
 ELANMP2: Ellagic acid dihydrate (50.0 mg, 0.15 mmol) was dissolved in 1 mL 
of NMP. The brown solution was left for slow evaporation. Yellow plate-like crystals 
(42.0 mg) were harvested after a week. 
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 ELAPG2: Ellagic acid dihydrate (10.0 mg, 0.15 mmol) was dissolved in 2 mL of 
(±)PG with heat. The yellow solution was filtered and left for slow evaporation. Yellow 
block crystals (5.0 mg) were harvested after a week. 
 
3.4.2 Crystal Form Characterization 
 Single crystals suitable for X-ray diffraction were selected using an optical 
microscope. The X-ray diffraction data were collected using Bruker-AXS 
SMART-APEX/APEXII CCD diffractometer with monochromatized Cu Kα radiation (λ 
= 1.54178Å) for all crystal samples, except for ELATPH•0.13H2O with 
monochromatized Mo Kα radiation (λ = 0.71073Å).  Indexing was performed using 
SMART v5.62537a or using APEX 2008v1-0.37b Frames were integrated with SaintPlus 
7.5138 software package. Absorption correction was performed by multiscan method 
implemented in SADABS. The structures were solved using SHELXS-97 (Direct 
methods) and refined using SHELXL-97 (full matrix nonlinear least-squares) contained 
in SHELXTL v6.1040 and WinGX v1.70.0141-43 program packages. All non-hydrogen 
atoms were refined anisotropically. 
 A Bruker AXS D8 X-ray powder diffractometer was used for all PXRD 
measurements with experimental parameters as follows: Cu Kα radiation (λ = 1.54056 Å); 
40 kV and 30 mA; detector type: scintillation type; scanning interval: 3° - 40° 2θ; time 
per step: 0.5 s. The experimental PXRD patterns and calculated PXRD patterns from 
single crystal structures were compared to confirm the composition of bulk materials. 
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 Thermal analysis was performed on a TA Instruments DSC 2920 differential 
scanning calorimeter. Aluminum pans were used for all samples and the instrument was 
calibrated using an indium standard. For reference, an empty pan sealed in the same way 
as the sample was used. Using inert nitrogen conditions, the samples were heated in the 
DSC cell from 30°C to 350°C at a rate of 10°C/min. 
 A Perkin-Elmer STA 6000 Simultaneous Thermal Analyzer was used to conduct 
thermogravimetric analysis. Open alumina crucibles were used to heat the samples from 
30°C to 350°C at a rate of 10°C/min under a nitrogen stream. 
 Characterization of the cocrystals by fourier transform infrared spectroscopy 
(FTIR) was accomplished with a Nicolet Avatar 320 FT-IR instrument. Sample amounts 
of 1-2 mg were used, and spectra were measured over the range of 4000-400 cm-1 and 
analyzed using EZ Omnic software. 
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Table 3-5. Selected hydrogen bond parameters for ellagic acid cocrystals. 
Compound Hydrogen bond d (H···A) / Å D (D···A) / Å θ / ° 
ELANAM 
N(7)-H(71)•••O(7)#2 2.17 3.044 (7) 176.5 
N(7)-H(72)•••O(15) 2.07 2.939 (7) 169.1 
O(17)-H(17)•••N(1)#3 1.59 (6) 2.634 (5) 174 (5) 
O(11)-H(11)•••O(7)#2 1.85 2.694 (6) 179.3 
#1 -x,-y,-z    #2 -x+1,-y,-z+2    #3 x-1/2,-y+1/2,z-3/2 
ELADMP 
O(2)-H(2)•••N(1)#3 1.58 (5) 2.588 (4) 163 (4) 
N(2)-H(1)•••O(4)#2 1.90 (5) 2.973 (4) 173 (4) 
#1 -x+2,-y+1,-z+1    #2 x,-y+1/2,z-1/2    #3 x,-y+1/2,z+1/2 
ELASAR 
N(1)-H(1N)•••O(7) 1.99 (2) 2.905 (3) 163 (3) 
N(1)-H(2N)•••O(8)#1 2.24 (2) 3.006 (3) 142 (3) 
O(6)-H(6)•••O(10)#2 1.79 2.595 (3) 160.6 
O(7)-H(7)•••O(9)#3 1.80 2.594 (2) 156.7 
O(8)-H(8)•••O(9)#4 1.93 2.714 (2) 154.5 
#1 x,y,z+1    #2 x,y-1,z-1    #3 -x,-y+1,-z+1 #4 -x,-y+1,-z 
ELADMG 
O(5)-H(3)•••O(10)#1 1.72 (2) 2.649 (1) 174 (2) 
O(6)-H(4)•••O(9)#2 1.86 (2) 2.682 (1) 157 (2) 
O(1)-H(1)•••O(9)#3 2.17 (2) 2.903 (2) 149 (2) 
O(2)-H(2)•••O(10)#4 1.63 (2) 2.587 (1) 170 (2) 
N(1)-H(5)•••O(5)#5 2.09 (2) 2.887 (2) 144 (2) 
#1 -x+1/2,-y+1/2,-z    #2 x,y+1,z    #3 x+1/2,y+1/2,z 
 #4 -x+1,-y+1,-z    #5 -x+1/2,y-1/2,-z+1/2 
ELACAP 
O(11)-H(11)•••O(1) 1.96 (11) 2.724 (9) 160 (11) 
N(1)-H(1N)•••O(17)#2 2.15 (11) 2.903 (10) 130 (8) 
O(12)-H(12)•••O(1)#4 1.98 (8) 2.696 (9) 171(9) 
#1 -x+1,-y+1,-z+1    #2 x-1/2,-y-1/2,z-1/2    #3 -x+1/2,y-1/2,-z+1/2 
 #4 -x+1/2,y+1/2,-z+1/2 
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Table 3-6. Selected hydrogen bond parameters for ellagic acid cocrystal 
solvates/hydrates. 
Compound Hydrogen bond d (H···A) / Å 
D (D···A) / 
Å θ / ° 
ELAINM•1.7H2O 
O(3)-H(3)•••O(11)#1 1.91 2.749 (2) 177.1 
O(4)-H(4)•••N(11) 1.86 2.611 (2) 147.8 
N(12)-H(12N)•••O(1)#2 2.03 (3) 2.930 (3) 174 (3) 
N(12)-H(13N)•••O(11)#3 2.06 (3) 2.988 (3) 173 (3) 
#1 -x-1,-y+1,-z    #2 -x,-y+1,-z+1    #3 -x-2,-y+2,-z 
ELAINM•4NMP 
N(4)-H(16)•••O(7)#4 2.01 (5) 2.923 (4) 176 (5) 
O(4)-H(17)•••N(3)#3 1.78 (6) 2.647 (4) 147 (5) 
N(4)-H(10)•••O(1)#2 1.97 (5) 2.827 (5) 166 (4) 
O(3)-H(15)•••O(2)#3 1.72 (6) 2.615 (4) 166 (5) 
#1 -x+2,-y+1,-z+1    #2 x+1,y,z+1    #3 x-1,y,z    #4 1-x,2-y,2-z 
ELAINM•4DMA 
N(2)-H(2A)•••O(1)#2 2.04 2.895 (3) 172.4 
N(2)-H(2B)•••O(51) 2.01 2.792 (7) 150.2 
O(3)-H(3)•••N(1) 1.916 (2) 2.647 (3) 148.1 (1)
O(4)-H(4)•••O(6) 1.790 (2) 2.608 (3) 177.3 (1)
#1 -x+1,-y+1,-z+2    #2 -x,-y+2,-z+1 
ELACAF•H2O 
O(2)-H(2)•••N(4)#1 1.93 2.702 (4) 151.7 
O(4)-H(4)•••O(6)#2 1.90 2.708 (3) 161.3 
O(7)-H(7)•••O(1W)#3 1.78 2.608 (3) 167.2 
O(8)-H(8)•••O(5)#4 1.93 2.701 (3) 152.4 
O(1W)-H(1W)•••O(3)#3 2.08 (2) 2.920 (4) 164 (4) 
O(1W)-H(2W)•••O(9) 1.99 (2) 2.854 (4) 162 (4) 
#1 x+1,y,z-1    #2 x,y,z-1    #3 x-1,y,z    #4 x,y+1,z 
ELATPH•0.13H2O 
N(4)-H(4)•••O(4)#2 1.80 (2) 2.714 (2) 169 (2) 
O(11)-H(111)•••O(2)#3 1.86 (3) 2.757 (2) 171 (2) 
O(12)-H(121)•••N(3)#4 1.82 (4) 2.711 (2) 166 (3) 
#1 -x+1,-y,-z+1    #2 -x+2,-y,-z+2    #3 -x+1/2,y-1/2,-z+3/2 
 #4 -x+1,-y,-z+2 
ELATPH•2DMA 
O(3)-H(3)•••N(13)#2 2.09 2.849 (3) 154.7 
O(4)-H(4)•••O(21)#3 1.75 2.548 (4) 165.6 
N(14)-H(14A)•••O(11)#4 1.95 2.804 (3) 170.0 
#1 -x+2,-y+1,-z+1    #2 x-1,y,z    #3 x,y-1,z 
 #4 -x+1,-y,-z 
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ELAURE•2NMP 
O(2)-H(2)•••O(11)#1 1.81 (6) 2.543 (5) 169 (7) 
O(6)-H(11)•••O(12)#2 1.99 (7) 2.684 (4) 160 (7) 
O(5)-H(10)•••O(10)#3 1.39 (8) 2.581 (4) 166 (7) 
O(1)-H(1)•••O(9)#4 2.05 (6) 2.657 (5) 164 (7) 
N(3)-H(3A)•••O(11)#5 2.061 (3) 2.899 (6) 164.6 (3)
N(4)-H(4B)•••O(6)#5 2.348 (3) 2.983 (5) 130.9 (3)
N(3)-H(3B)•••O(8)#5 2.256 (3) 3.058 (5) 155.4 (3)
N(2)-H(2A)•••O(12) 2.064 (3) 2.922 (5) 175.9 (3)
N(1)-H(1A)•••O(12)#3 2.248 (3) 2.959 (6) 139.9 (3)
#1 x,1+y,z    #2 x,-1+y,z    #3 -1+x,y,z    #4 1-x,1-y,-z 
#5 1-x,-y,-z 
  
Table 3-7. Selected hydrogen bond parameters for ellagic acid solvates. 
Compound Hydrogen bond d (H···A) / Å 
D (D···A) / 
Å θ / ° 
ELADMA4 
O(3)-H(20)•••O(2)#2 1.70 2.5770 (16) 170.4 
O(4)-H(21)•••O(1)#2 2.01 2.6148 (16) 129.9 
#1 -x,-y+2,-z    #2 -x+1,y+1/2,-z+1/2 
ELADMA2 
O(1)-H(1)•••O(5)#2 1.83 2.6696 (14) 172.8 
O(2)-H(2)•••O(5) 2.08 2.8393 (14) 149.9 
#1 -x,-y+2,-z+2    #2 -x+1,-y+1,-z+2 
ELADMSO2 
O(11)-H(11)•••O(1)#2 1.87 (5) 2.674 (3) 169 (5) 
O(12)-H(12)•••O(1)#3 1.97 (5) 2.695 (3) 153 (5) 
#1 -x+1,-y+2,-z+1    #2 x+1,y,z    #3 -x+2,-y+1,-z+1 
ELANMP2 
O(1)-H(1)•••O(5)#2 2.09 (6) 2.745 (4) 150 (6) 
O(2)-H(2)•••O(5)#3 2.01 (6) 2.697 (4) 172 (8) 
#1 -x+1,-y,-z    #2 x,y+1,z    #3 -x+1/2,y+1/2,-z+1/2 
ELAPG2 
O(21)-H(21)•••O(14)#2 1.99 (5) 2.734 (3) 166 (5) 
O(12)-H(12)•••O(22)#3 1.84 (5) 2.660 (3) 164 (4) 
O(11)-H(11)•••O(21)#4 1.75 (5) 2.602 (3) 171 (5) 
#1 -x+1,-y+1,-z    #2 x,y+1,z    #3 x+1,y-1,z    #4 x+1,y,z 
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Table 3-8. Crystallographic data for ellagic acid cocrystals. 
 ELANAM ELADMP ELASAR ELADMG ELACAP 
Formula C26H18N4O10 C24H22N4O8 C17H13NO10 C18H15NO10 C26H28N2O10
MW 546.44 494.46 391.28 405.31 528.51 
Crystal 
system Monoclinic Monoclinic Triclinic Monoclinic Monoclinic 
Space group P21/n P21/c P1ത C2/c P21/n 
a (Å) 7.035 (3) 4.9393 (6) 7.6115 (2) 20.7781 (4) 12.452 (3) 
b (Å) 22.963 (6) 18.155 (2) 9.4592 (2) 12.4012 (2) 6.0627 (15) 
c (Å) 7.290 (2) 12.1795 (12) 11.5037 (3) 13.0557 (2) 15.624 (4) 
 (deg) 90 90 105.294 (2) 90 90 
 (deg) 106.50 (2) 93.451 (7) 109.068 (2) 107.333 (1) 91.562 (10) 
 (deg) 90 90 91.848 (2) 90 90 
V /Å3 1129.2 (6) 1090.2 (2) 748.69 (3) 3211.34(9) 1179.1 (5) 
Dc/mg m-3 1.607 1.506 1.736 1.677 1.489 
Z 2 2 2 8 2 
2 range 3.85 to 39.04 
4.38 to 
68.14 
4.25 to 
63.65 
4.20 to 
65.08 
4.48 to 
42.87 
Nref./Npara. 623 / 172 1916 / 178 2369 / 263 2695 / 285 753 / 212 
T /K 100 (2) 100 (2) 100 (2) 100 (2) 100 (2) 
R1 
[I>2sigma(I)] 0.0375 0.0636 0.0431 0.0313 0.0515 
wR2 0.0771 0.1404 0.1032 0.0844 0.1346 
GOF 1.011 1.002 1.001 1.030 1.065 
Abs coef. 1.077 0.972 1.269 1.206 0.974 
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Table 3-9. Crystallographic data for ellagic acid cocrystal solvates/hydrates. 
 ELAINM •1.7H2O 
ELAINM 
•4NMP 
ELAINM 
•4DMA 
ELACAF 
•H2O 
Formula C26H21.4N4O11.7 C46H54N8O14 C42H54N8O14 C22H18N4O11 
MW 574.65 942.97 894.93 514.40 
Crystal system Triclinic Triclinic Triclinic Triclinic 
Space group P1ത P1ത P1ത P1ത 
a (Å) 3.6207 (2) 6.6365 (2) 6.6402 (4) 9.705(3) 
b (Å) 12.4908 (6) 10.6281 (3) 10.4995 (6) 10.926(5) 
c (Å) 13.5227 (6) 16.1445 (4) 16.2469 (8) 11.469(7) 
 (deg) 72.641 (3) 87.391 (2) 86.469 (3) 104.74(3) 
 (deg) 89.258 (3) 87.722 (2) 86.959 (3) 95.68(3) 
 (deg) 83.979 (3) 78.243 (2) 78.012 (3) 113.80(3) 
V /Å3 580.39 (5) 1113.14 (5) 580.39 (5) 1047.9 (9) 
Dc/mg m-3 1.644 1.407 1.345 1.630 
Z 1 1 1 2 
2 range 3.42 to 65.36 2.74 to 67.72 2.73 to 68.33 4.09 to 65.36 
Nref./Npara. 1916 / 210 3735 / 395 3710 / 354 3301  / 349 
T /K 100(2) 100(2) 100(2) 100(2) 
R1 [I>2sigma(I)] 0.0439 0.0798 0.0593 0.0549 
wR2 0.1093 0.2067 0.1638 0.1380 
GOF 1.037 1.052 1.052 1.013 
Abs coef. 1.136 0.881 0.855 1.150 
 ELATPH 
•0.07H2O 
ELATPH 
•2DMA 
ELAURE 
•2NMP 
 
Formula C28H2N8O12.13 C36H40N10O14 C52H64N12O24  
MW 664.62 836.75 620.57  
Crystal system Monoclinic Triclinic Triclinic  
Space group P21/n P1ത P1ത  
a (Å) 11.636 (3) 4.543 (3) 7.1468 (7)  
b (Å) 6.8183 (19) 12.373 (6) 13.1766 (11)  
c (Å) 16.868 (5) 17.486 (8) 14.7365 (12)  
 (deg) 90 104.923 (8) 88.038 (5)  
 (deg) 95.607 (6) 94.003 (13) 79.457 (6)  
 (deg) 90 93.217 (12) 86.578 (6)  
V /Å3 1331.9 (6) 944.6 (8) 1361.5 (2)  
Dc/mg m-3 1.657 1.471 1.514  
Z 2 1 2  
2 range 2.04 to 25.03 2.63 to 65.49 3.05 to 67.71  
Nref./Npara. 2339 / 271 3207 / 296 4548 / 416  
T /K 100(2) 100(2) 100 (2)  
R1 [I>2sigma(I)] 0.0474 0.0576 0.0916  
wR2 0.1108 0.1438 0.1966  
GOF 1.099 1.013 1.459  
Abs coef. 0.133 0.979 1.035  
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Table 3-10. Crystallographic data for ellagic acid solvates. 
 ELADMA4 ELADMA2 ELADMSO2 ELANMP2 ELAPG2 
Formula C30H42N4O12 C22H24N2O10 C18H18O10S2 C24H24N2O12 C20H22O12 
MW 650.68 476.43 458.44 500.46 454.38 
Crystal 
system Monoclinic Triclinic Triclinic Monoclinic Triclinic 
Space group P21/c P1ത P1ത P21/n P1ത 
a (Å) 11.2531 (1) 7.0277 (1) 5.040 (2) 12.7369 (6) 5.0201 (4) 
b (Å) 7.9074 (1) 7.8128 (1) 10.095 (5) 6.1858 (3) 7.2345 (5) 
c (Å) 18. 9832 (3) 10.8493 (2) 10.304 (4) 14.1230 (8) 13.8053 (10) 
 (deg) 90 90.697 (1) 71.61 (3) 90 74.893 (5) 
 (deg) 109.448 (1) 107.440 (1) 77.13 (3) 96.182 (4) 87.069 (5) 
 (deg) 90 113.140 (1) 76.07 (3) 90 77.273 (6) 
V /Å3 1592.80 (4) 516.822 (14) 476.7 (3) 1106.25 (10) 472.15 (6) 
Dc/mg m-3 1.357 1.531 1.597 1.502 1.598 
Z 2 1 1 2 1 
2 range 4.17 to 68.23 4.32 to 66.26 4.58 to 65.03 4.44 to 65.63 3.32 to 63.64 
Nref./Npara. 2843 / 214 1716 / 159 1520 / 146 1878 / 172 1459 / 162 
T /K 100 (2) 100 (2) 100 (2) 100 (2) 100 (2) 
R1 
[I>2sigma(I)] 0.0460 0.0374 0.0440 0.0687 0.0464 
wR2 0.1279 0.1077 0.1066 0.2169 0.1058 
GOF 1.088 1.106 1.025 1.389 1.060 
Abs coef. 0.887 1.041 3.065 1.005 1.157 
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Chapter 4. Ionic Cocrystals: Crystal Forms of Lithium Salts 
 
4.1 Preamble 
 Bipolar disorder138 affects more than one percent of the population, is a disabling 
mental illness characterized by alternating “mood swings” between periods of elevated or 
irritable mood (mania) and periods of depression. These mood swings can be very abrupt 
with occasional suicidal tendencies. There are three types of bipolar disorder (type I, II 
and cyclothymic), differing only in the severity of the mood swings. Type I involves at 
least one manic or mixed episode (mania and depression occurring simultaneously) and 
one or more depressive episodes, that lasts for at least 7 days in a regular alternating 
pattern. Untreated patients average 4 episodes of mood swings each year with untreated 
mania lasting at least one week to months while depressive episodes can last 6 to 12 
months. Type II involves major depressive episodes with occasional hypomania episodes, 
lasting at least 4 days. Patients suffer from significantly more depressive episodes with 
shorter periods of well-being between episodes compared to type I patients, leading to a 
higher risk for suicidal tendencies. Cyclothymic disorder is less severe compared to types 
I and II but is more chronic. It can deteriorate to type I or II in some patients or remain a 
mild chronic condition. In addition, there is bipolar disorder not otherwise specified 
(NOS) that does not fit into the three categories and bipolar disorder with rapid cycling. 
Bipolar disorder with rapid cycling is a temporary condition with at least 4 rapid 
alternating manic, hypomania or depressive episodes in a year.139  
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 Lithium (especially carbonate and citrate salts) remains the “gold standard” for 
the treatment of bipolar disorder and the prevention of relapses in patients.140 Further, it is 
the only medication that consistently reduces suicidality in recurrent unipolar major 
depressive disorder and in bipolar disorder.141 Lithium is readily absorbed from the 
gastrointestinal tract and attains its maximum concentration between ½ to 3 hours. 
However, lithium treatment suffers from a narrow therapeutic index with a therapeutic 
serum level between 0.5 mM to 1.5 mM. Lithium intoxication occurs with a serum level 
of ≥ 2.0 mM. Animal studies with adult male Sprague-Dawley rats indicate lithium takes 
about 2 hours (Tmax) to achieve maximum serum concentration (Cmax) but 24 hours for 
maximum brain concentration.142 That lithium experiences difficulty in crossing the 
blood brain barrier coupled with the narrow therapeutic index, means any patient on 
lithium treatment for bipolar disorder must be monitored constantly to guard against 
lithium intoxication. From a clinical perspective, the Cmax in blood serum should best be 
quickly followed by the Cmax in brain, i.e., the time difference between the Tmax for blood 
serum and brain should be minimal. 
 
4.1.1 Amino acids as the ideal cocrystal formers 
 A pharmaceutical cocrystal143 is a cocrystal in which a pharmaceutically 
acceptable cocrystal former forms a supramolecular synthon48 with an API. That there are 
active transporters to facilitate the movement of amino acids across the blood brain 
barrier144 implies that intuitively, amino acids may be the appropriate cocrystal formers to 
target ionic cocrystals145 of lithium salts. Furthermore, amino acids as dipolar zwitterions 
84 
 
are ideally suited to engage the lithium cation via the negatively-charged carboxylate 
while the positively-charged ammonium interact with the counteranion, thus segregating 
the lithium cation from its counteranion by acting as a spacer. In an aqueous 
environment, the carboxylic acid moiety of the amino acid undergoes deprotonation 
readily with simultaneous protonation of the amine moiety. In essence, the amino acid is 
a zwitterion that is dipolar with a positive-charged ammonium group and a negative-
charged carboxylate moiety and has a total net charge of zero. The carboxylate moiety 
will bind strongly to the lithium cation due to its oxophilic character, leaving the 
ammonium group to hydrogen bond with the counteranion. Lithium chloride is the 
primary objective since the chloride anion is abundant in stomach acid. In addition, other 
pharmaceutically acceptable anions such as bromide and nitrate will also be studied. 
 
4.1.2 CSD survey of ionic cocrystals of LiX (X = Cl-, Br- and NO3-) and amino 
acids 
 The coordination chemistry of the lithium146 cation has been reviewed to provide 
in-depth analysis of the bond length, geometry, coordination number and solvent of 
crystallization of lithium complexes based on X-ray crystallographic data. The 
coordination numbers of lithium complexes range from 4 to 8. But it prefers the 4-
coordinate tetrahedral coordination mode which is the most frequently encountered. The 
lithium cation is defined as a hard acid.147-149 Thus lithium cations are expected to bond to 
the oxygen atoms of ligands. A survey of the Cambridge Structural Database (CSD) on 
lithium chloride/bromide/nitrate complexes with amino acids and peptides reveals the 
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coordination of the bridging carboxylates onto lithium cations while hydrogen bonding 
interaction between the anions and the ammonium groups serves to reinforce the crystal 
packing forces. 
Table 4-1. Ionic cocrystals of lithium salts from the CSD. 
Lithium Salt Amino Acid Lithium: Amino 
Acid Stoichiometry 
CSD Refcode 
 
LiCl 
Glycine 1:1 HEFWUK150 
GLY-GLY 1:1 HEFXEV150 
L-proline 1:1 YOXBET151 
 
LiBr 
ALA-GLY 1:1 ALGLYL152 
GLY-GLY 1:1 GLYGLB 
GLY-GLY-GLY 1:1 GLYLIB 
LiNO3 Glycine 1:1 ALUNEA153 
Glycine 1:2 ROZTUW154 
 
 
Figure 4-1. A chain of fused six-atom rings in HEFWUK (top) and alternating 
eight-atom and four-atom rings in ALUNEA (bottom). 
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 Analysis of these crystal structures reveals the lithium cations in the 4-coordinate 
tetrahedral coordination environment. The carboxylates bridge adjacent lithium cations to 
form either a chain of fused six-atom rings or a chain of alternating eight-atom and four-
atom rings. This is a dominant feature in the 1:1 ionic cocrystals of lithium salts and 
amino acids discussed in this chapter. 
 
4.1.3 1:2 ionic cocrystals of LiX (X = Cl-, Br- and NO3-) and amino acids as 
structural analogues of zeolites and silica 
 The interest in developing ionic cocrystals of lithium salts is two-fold. From a 
materials design perspective, lithium is the lightest metal in the periodic table that prefers 
to adopt a 4-coordinate tetrahedral environment. The attention is drawn to zeolites 
(aluminosilicates) and silica (SiO2) as manifestations of tetrahedral nodes to create a rich 
diversity of 3-periodic architectures. Synthetic inorganic zeolites typically consist of 
oxide anions that link tetrahedral aluminum or silicon cations (nodes) in a 2:1 ratio.155 
The key to the existence of microporosity in zeolites is that the oxide linkers are angular 
(M-O-M angles typically range from 140° to 165°), thereby facilitating the generation of 
a wide range of topologies that are based upon rings, fused rings and polyhedral cages. 
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Figure 4-2. Secondary building units (SBUs) in zeolites. 
 
 Which particular topology exists for a given chemical composition is typically 
controlled by reaction conditions, counterions and/or structure directing agents156 
(SDAs).  The absence of counterions, SDAs or the use of a linear linker more typically 
manifests the tetrahedral node in the form of a diamondoid (dia) net157-158 that, unlike 
most zeolitic topologies, can interpenetrate to mitigate the creation of free space. 
 The ground rules for generating zeolitic and/or dia networks are therefore self-
evident and they have been validated across a remarkably diverse range of tetrahedral 
nodes (e.g. phosphates159, transition metal cations160-162, metal clusters163) and linkers 
(including purely organic ligands that form coordination bonds164 or hydrogen bonds165-
167). Coordination polymers that exploit the diversity of tetrahedral moieties and angular 
Frequency of 
occurrence 
given in 
parentheses 
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or linear organic ligands have recently afforded new levels of scale that includes new 
classes of zeolitic structures with hitherto unattainable levels of porosity. Such zeolitic 
metal-organic materials are exemplified by zeolitic imidazolate frameworks168-170 (ZIFs), 
boron imidazolate frameworks171 (BIFs), zeolite-like metal-organic frameworks172 
(ZMOFs) and the zeolite NPO sustained by metal-carboxylate clusters only (denoted as 
CPM = crystalline porous material)173. ZIFs are based upon imidazolate ligands that 
subtend an angle of ca. 145° whereas the prototypal ZMOFs use 4,5-imidazole-
dicarboxylate174 and pyrimidine-based ligands175-176 in the presence of SDAs to 
coordinate to 8-coordinate metals such as In and Cd. BIFs are inherently of low density 
because they are based upon tetrahedral boron atoms. 
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Figure 4-3. Synthetic zeolite based on imidazolates, LTA (top left), RHO, (top right), 
RHO (BIF-9-Li, bottom left), SOD (bottom right). Yellow spheres highlight the 
empty polyhedral cages. 
 
  Tetrahedral nodes are also found in several crystalline forms (polymorphs) of 
silica (SiO2). Among them, quartz is the only stable form under ambient conditions. 
Under normal pressure conditions, α-quartz (trigonal polymorph) converts to β-quartz 
(hexagonal polymorph) at 573°C which further converts to β-tridymite (hexagonal 
polymorph) at 870°C. β-tridymite exhibits the rarely encountered lonsdaleite177-178 (lon) 
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net. At 1470°C, β-tridymite converts to β-cristobalite (cubic polymorph) which exhibits 
the dia net and finally melts at 1705°C.179 The multitude of 3-periodic architectures from 
zeolites and silica has been constructed from heavy atoms. That low density is a desirable 
property means that lithium, the lightest metal in the periodic table, is a particularly 
attractive target to serve as a tetrahedral node in either zeolitic or dia networks. 
 
Figure 4-4. Polymorphs of silica, β-cristobalite (top left), β-tridymite (top right), β-
quartz, (bottom left), faujasite (bottom right). 
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 Lithium forms many air and water stable coordination environments and not all 
existing zeolitic metal-organic materials are water stable. In this context, a prototypal 
structure was reported by Pinkerton et al., who isolated a lithium-based zeolitic ABW 
network with hexachlorotantalum anion embedded in what was described as a three-
dimensional Li-Cl-dioxane network180. However, this compound is extremely moisture 
sensitive. Bu and coworkers addressed the challenge elegantly in BIFs by employing both 
lithium and boron with imidazolates in BIF-9-Li, a compound with RHO topology181. 
Other approaches to low density porous materials based upon lithium include the 
following: Robson et al. reported a microporous lithium isonicotinate with square 
channels182; Henderson and coworkers isolated a pillared bilayer and a diamondoid net 
with solvated lithium aryloxides183; Parise et al. reported a MOF based on lithium and 
2,5-pyridinedicarboxylic acid that loses porosity upon solvent removal184. 
 A new and general strategy to build lithium based zeolitic metal-organic materials 
(LiZMOMs) and lithium based diamondoid metal-organic materials (LiDMOMs) by 
exploiting the Li-carboxylate-Li linkages that can be formed when amino acid zwitterions 
form cocrystals with lithium salts is described. The strategy described herein is based 
upon generating compounds in which there is a stoichiometric ratio of one lithium cation 
and two carboxylate anions. That carboxylate moieties can sustain dia nets is exemplified 
in a series of divalent metal formates that naturally possess the required 2:1 ratio of linker 
to node185-186. Indeed, such structures can even exhibit the rarely encountered 
lonsdaleite177-178 (lon) topology. However, that lithium is monovalent means that the 
requisite 2:1 ratio of linker to node will be very difficult to achieve with anionic linkers. 
Again, Bu and coworkers circumvented this issue by supplementing neutral lithium 
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imidazolates with neutral bifunctional N-donor ligands.187 The charge of the linker will 
not be an issue by using the carboxylate moieties in amino acids, i.e. neutral zwitterions, 
to bridge two lithium cations. The target is a new class of compound: 2:1 cocrystals of 
amino acids and inorganic lithium salts. The use of amino acids provides numerous 
advantages and opportunities: 1) many amino acids are commercially available and they 
are typically inexpensive; 2) Figure 5 reveals that lithium- carboxylate-lithium angles 
offer the requisite diversity needed to generate a wide range of extended structures; 3) the 
lithium-carboxylate bond is robust even in the presence of water; 4) amino acids possess 
functionalized side chains that facilitates fine-tuning of the resulting structures through 
pre-synthetic methods; 5) the abundance of homochiral amino acids means that 
homochiral crystals with optical activity and bulk polarity are guaranteed; 6) most amino 
acids are soluble in water, therefore facilitating green synthesis; 7) the charge of the 
network is inverted compared to zeolites because the framework is cationic and the 
required counterions are anions, i.e. anion exchange becomes feasible. The remarkable 
range of Li-carboxylate-Li angles stems partly from the tendency of the carboxylate 
ligand to exhibit either endodentate or exodentate bridging modes. 
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Figure 4-5. Distribution of the Li-C-Li angle in crystal structures that contain 
lithium cations bridged by carboxylate moieties (data obtained using CSD version 
5.31). 
 
4.2 Results and Discussion 
Table 4-2. Table of zwitterionic cocrystal formers. 
H2+
N
O-
O
 
SAR 
NH+
O-
O
 
DMG 
N+
O-
O
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+H3N O-
O
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N
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O-  
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 The amino acids listed in table 4-2 are combined with lithium salts in two distinct 
stoichiometries to achieve a wide variety of ionic cocrystals. 
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4.2.1 1:1 ionic cocrystals of LiX and amino acids: A discrete supermolecule and 
linear chains 
 A series of 1:1 ionic cocrystals and cocrystal hydrates of lithium salts (lithium 
chloride, LIC, lithium bromide, LIB and lithium nitrate, LIN) and amino acids (sarcosine, 
SAR, N,N-dimethylglycine DMG, betaine, BTN, β-alanine, BAL, 4-aminobutyric acid 
and L-proline, PRO) are synthesized and characterized. A discrete assembly and 1-
periodic chains were obtained from these 1:1 cocrystals and cocrystal hydrates.  
 
Figure 4-6. A chain of fused six-atom rings is observed in LICSAR. 
 
 LICSAR: The crystal structure reveals that LICSAR is a 1:1 lithium chloride and 
sarcosine cocrystal monohydrate. Each lithium cation is bridged by three carboxylates 
[Li-O: 1.895(12) Å, 1.932(13) Å and 1.959(13) Å] with one coordinated water molecule 
[Li-O: 1.960(12) Å] to fulfill the 4-coordinate tetrahedral environment. It forms a chain 
of fused six-atom rings. Adjacent chains are linked by hydrogen bonding interaction 
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between the chloride anions and the ammonium groups [NH•••Cl: 3.145(5) Å and 
3.114(5) Å] and OH(water) •••O(carboxylate) interaction [2.951(7) Å]. 
 
Figure 4-7. The nitrate anions coordinate to the lithium cations in LINSAR. 
 
 LINSAR: Analysis of the crystal structure reveals a 1:1 cocrystal of lithium 
nitrate and sarcosine. Each lithium cation is bridged by three carboxylates [Li-O: 
1.939(4) Å, 1.952(4) Å and 1.956(5) Å] with one coordinated nitrate anion [Li-O: 
2.017(5) Å] to fulfill the 4-coordinate tetrahedral environment. It forms a chain of fused 
six-atom ring. Adjacent chains are linked by hydrogen bonding interaction between the 
nitrate anions and the ammonium groups [NH•••O: 2.896(3) Å and 2.918(3) Å]. 
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Figure 4-8. Li2(DMG)2 clusters are hydrogen bonded into a 1-periodic structure. 
 
 LICDMG: The X-ray structure reveals a dihydrate of a 1:1 cocrystal of lithium 
chloride and N,N-dimethylglycine. Each lithium cation is bridged by the same pair of 
carboxylates [Li-O: 1.926(3) Å and 1.932(2) Å] with two coordinated water molecules 
[Li-O: 1.909(3) Å and 1.943(3) Å] to establish a discrete supermolecular assembly. 
OH(water)•••O(carboxylate) [2.7543(14) Å] interactions align these discrete units into a 
linear chain. The chloride anions act as hydrogen bond acceptors towards three water 
molecules [OH•••Cl: 3.1264(12) Å, 3.1452(12) and 3.1686(11) Å] and an ammonium 
group [NH•••Cl: 3.2204(12) Å] to tether adjacent chains together. 
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Figure 4-9. The nitrate anions are coordinated to the lithium cations in LINDMG. 
 
 LINDMG: The crystal structure reveals a 1:1 cocrystal of lithium nitrate and N,N-
dimethylglycine.. Each lithium cation is bridged by three carboxylates [Li-O: 1.919(3) Å, 
1.934(3) Å and 1.937(3) Å] with one coordinated nitrate anion [Li-O: 1.977(3) Å] to 
fulfill the 4-coordinate tetrahedral environment. It forms a chain of fused six-atom ring. 
Adjacent chains are linked by hydrogen bonding interaction between the nitrate anions 
and the ammonium groups [NH•••O: 2.8349(1) Å]. 
 
Figure 4-10. An undulating chain is constructed by bridging discrete (LiCl)2·(H2O)2 
clusters with betaine zwitterions. 
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 LICBTN: The X-ray structure reveals a 2:1 lithium chloride and betaine cocrystal 
dihydrate. Each lithium cation is coordinated by a bridging carboxylate [Li-O: 1.849(5) Å 
and 1.865(6) Å], two water molecules [Li-O: 1.997(5) Å, 2.023(5) Å and 2.011(5) Å] and 
a coordinated chloride anion [Li-Cl: 2.319(4) Å and 2.329(4) Å]. Two lithium cations and 
two bridging water molecules form a four-atom ring cluster. The four-atom ring cluster 
alternates with bridging carboxylates to form an undulating chain. Each chloride anion 
accepts two hydrogen bonds from bridging water molecules [OH•••Cl: 3.065(2) Å, 
3.117(2) Å, 3.120(2) Å and 3.178(2) Å] to crosslink adjacent chains. Crystals of LICBTN 
deliquesce within minutes and do not allow further analysis to be possible. 
 
Figure 4-11. A chain of fused alternating eight-atom rings and four-atom rings in 
LICBAL-anhydrate. 
 
 LICBAL-anhydrate: X-ray analysis reveals a 1:1 cocrystal of lithium chloride and 
β-alanine. Each lithium cation is bridged by three carboxylates [Li-O: 1.915(3) Å, 
1.920(3) Å and 1.942(3) Å] with a coordinated chloride anion [Li-Cl: 2.304(3) Å] to 
attain tetrahedral coordination environment. An eight-atom ring is constructed from two 
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lithium cations and two bridging carboxylates. Adjacent eight-atom rings are connected 
by forming a four-atom ring to yield a chain. Adjacent chains are linked by hydrogen 
bonding interaction between the ammonium groups with chloride anions [NH•••Cl: 
3.1983(14) Å and 3.2433(14) Å] and adjacent carboxylates [NH•••O: 2.8251(17) Å]. 
 
Figure 4-12. Water molecules coordinate to the lithium cations in LICBAL. 
 
 LICBAL: The crystal structure reveals a 1:1 lithium chloride and β-alanine 
cocrystal monohydrate. Each lithium cation is bridged by three carboxylates [Li-O: 
1.928(3) Å, 1.933(3) Å and 1.943(3) Å] with one coordinated water molecule [Li-O: 
2.002(3) Å] to fulfill the 4-coordinate tetrahedral environment. It forms a chain of fused 
six-atom rings. Adjacent chains are linked by hydrogen bonding interaction between the 
chloride anions and the ammonium groups. Each chloride anion acts as hydrogen bond 
acceptors towards two water molecules [OH•••Cl: 3.1262(17) Å and 3.2458(14) Å] and 
two ammonium groups [NH•••Cl: 3.222(2) Å and 3.2475(15) Å]. 
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Figure 4-13. The chloride anions are coordinated to the lithium cations in LICABA. 
 
 LICABA: Analysis of the crystal structure reveals a 1:1 cocrystal of lithium 
chloride and 4-aminobuytric acid. Each lithium cation is bridged by three carboxylates 
[Li-O: 1.900(3) Å, 1.965(3) Å and 1.976(3) Å] with one coordinated chloride anion [Li-
Cl: 2.289(2) Å] to achieve the tetrahedral coordination geometry. It forms a chain of 
fused six-atom rings. Adjacent chains are crosslinked by hydrogen bonding interaction 
between the ammonium groups acting as hydrogen bond donors towards neighbouring 
chloride anions [NH•••Cl: 3.1516(13) Å and 3.1886(13) Å] and adjacent carboxylates 
[NH•••O: 2.7970(16) Å]. 
 LICPRO: The crystal structure reveals a 1:1 lithium chloride and L-proline 
cocrystal monohydrate. Each lithium cation is bridged by three carboxylates [Li-O: 
1.956(5) Å, 1.962(7) Å and 1.993(8) Å] with one coordinated water molecule [Li-O: 
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1.996(5) Å] to fulfill the 4-coordinate tetrahedral environment. It forms a chain of fused 
six-atom rings. Adjacent chains are crosslinked by hydrogen bonding interaction between 
the chloride anions and the ammonium groups. Each chloride anion acts as hydrogen 
bond acceptors towards two water molecules [OH•••Cl: 3.194(3) Å and 3.234(3) Å] and 
two ammonium groups [NH•••Cl: 3.187(3) Å]. 
 
Figure 4-14. A chain of fused six-atom rings in LICPRO (top) and LIBPRO 
(bottom). 
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 LIBPRO: X-ray analysis reveals a monohydrate of 1:1 cocrystal of lithium 
bromide and L-proline. Each lithium cation is bridged by three carboxylates [Li-O: 
1.937(4) Å, 1.941(4) Å, 1.950(5), 1.970(6) and 1.987(6) Å] with one coordinated water 
molecule [Li-O: 1.939(4) Å and 1.971(4) Å] to fulfill the 4-coordinate tetrahedral 
environment. It forms a chain of fused six-atom rings. Adjacent chains are linked by 
hydrogen bonding interaction between the bromide anions and the ammonium groups. 
Each bromide anion acts as hydrogen bond acceptors towards two water molecules 
[OH•••Br: 3.312(3) Å, 3.322(3) Å, 3.345(3) Å and 3.353(3) Å] and two ammonium 
groups [NH•••Br: 3.277(3) Å, 3.289(3) Å and 3.326(3) Å]. 
 
Figure 4-15. An adamantane cage (left) is constructed with L-proline zwitterions and 
nitrate anions as bridging ligands, hexagonal channels in the dia net (right) are 
occupied by the pyrrolidinium ring of the zwitterions to mitigate interpenetration. 
 
 LINPRO: The X-ray structure reveals a 1:1 lithium nitrate and L-proline cocrystal. 
Each lithium cation is bridged by two carboxylates [Li-O: 1.882(3) Å and 1.888(3) Å] 
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and two nitrate anions [Li-O: 1.974(3) Å and 1.998(3) Å] to form a neutral mixed ligand 
dia net with distorted hexagonal channels exhibiting diameters ranging from 5.095 Å to 
9.288 Å, populated by the pyrrolidinium ring of the zwitterions [figure 4-15(right)]. The 
framework is reinforced by hydrogen bonding between the ammonium of an amino acid 
with an adjacent carboxylate [N-H···O: 2.898(2) Å] of another amino acid and a 
neighbouring nitrate anion [N-H···O: 2.842(2) Å]. The presence of pairs of zwitterions in 
these hexagonal channels interacting with the framework renders interpenetration 
impossible. 
 
4.2.2 1:2 ionic cocrystals of LiX and amino acids: Square grids, Diamondoids and 
a Zeolitic ABW net 
 In principle, 1:2 cocrystals of lithium salts and amino acids fit the criteria for 
formation of dia and/or zeolitic frameworks. However, another structural feature of 
zeolites is the presence of one or more rings, typically 4-, 6- or 8-membered MnOn rings. 
4-membered Li4(carboxylate)4 rings have previously been observed in a 1:2 cocrystal of 
lithium nitrate and glycine demonstrating a square grid network154 (Refcode ROZTUW, 
Li-C-Li angles 115.88°, 117.83°). With the structural prerequisites for self-assembly of 
zeolitic and/or dia networks in mind, a series of 1:2 ionic cocrystals of lithium salts (LIC, 
LIB and LIN) and amino acids (SAR, DMG, BTN and PRO) are synthesized and 
characterized. Cocrystals of the desired stoichiometry were prepared by slow evaporation 
of aqueous solutions of LIC, LIB or LIN and two equivalents of the amino acid at ca. 
80oC. These cocrystals are stable to at least 200C and are freely soluble in water. 
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Crystallographic analysis of the products revealed that three distinct networks were 
observed: square grids based upon only 4-membered Li4(carboxylate)4 rings; diamondoid 
networks based upon only Li6(carboxylate)6 rings; a zeolitic ABW network based upon 4-
membered, 6-membered and 8-membered Lin(carboxylate)n (n=4, 6 and 8) rings. 
 
Figure 4-16. Structural diversity in the networks formed by 1:2 cocrystals of lithium 
salts with amino acids: (a) square grids; (b) diamondoid LiDMOM nets; (c) zeolitic 
ABW topology in the first LiZMOM. Hydrogen atoms and counteranions are 
omitted for clarity. 
 
 
Figure 4-17. Undulating square grid (left) and bilayered packing arrangement 
(right) in LICSAR2. 
(a)        (b)    (c) 
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 LICSAR2: Each lithium cation is bridged by four carboxylates [Li-O: 1.905(3) Å, 
1.916(3) Å, 1.928(3) Å and 1.966(3) Å] to form an undulating square grid [figure 
4.17(left)], while the opposite ends of the amino acids point away (above and below) 
from the square grid to establish a bilayer packing arrangement [figure 4.17(right)]. The 
chloride anions reside at the interface of the ammonium groups, sustained by N-H···Cl 
[3.1011(1) Å, 3.1549(1) Å] interactions. These square cavities are about 5.0 Å by 6.0 Å 
and form undulating sheets that stack in a roughly eclipsed manner. 
 
Figure 4-18. Undulating square grid (left) and bilayered packing arrangement 
(right) in LINBTN2. 
 
 LINBTN2: Each lithium cation is bridged by four carboxylates [Li-O: 1.931(3) Å, 
1.933(3) Å, 1.958(3) Å and 1.973(3) Å] to form an undulating square grid [figure 4-
18(left)], while the opposite ends of the amino acids point away (above and below) from 
the square grid to establish a bilayer packing arrangement [figure 4-18(right)]. The nitrate 
anions reside at the interface of the ammonium groups, sustained by C-H···O [3.154(2) Å 
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to 3.606(2) Å] interactions. These square cavities are about 5.5 Å by 5.7 Å and form 
undulating sheets that stack in a roughly eclipsed manner. 
 
Figure 4-19. Hexagonal channels in dia nets of LICDMG2 (left) and LIBDMG2 
(right). 
 
 
 LICDMG2: Each lithium cation is bridged by four carboxylates [Li-O distances: 
1.898(3)Å and 1.910(3)Å] to form a cationic dia net with hexagonal channels exhibiting 
diameters ranging from 10.6 Å to 12.0 Å, populated by the chloride anions [figure 4-19 
(left)]. The framework is reinforced by hydrogen bonding between the carboxylate of one 
amino acid and the ammonium of an adjacent amino acid [N-H···O, 2.742(2) Å]. The 
presence of pairs of chloride anions [C-H···Cl, 3.628(3) Å, 3.633(2) Å and 3.635(2) Å] in 
these hexagonal channels interacting with neighbouring methyl groups renders 
interpenetration impossible. 
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 LIBDMG2: Each lithium cation is bridged by four carboxylates [Li-O: 1.908(3) Å 
and 1.942(3) Å] to form a cationic dia net with hexagonal channels exhibiting diameters 
ranging from 10.7 Å to 12.1 Å, populated by the bromide anions [figure 4-19(right)]. The 
framework is reinforced by hydrogen bonding between the carboxylate of one amino acid 
and the ammonium of an adjacent amino acid [N-H···O, 2.747(2) Å]. The presence of 
pairs of bromide anions [C-H···Br, 3.716(3) Å, 3.731(2) Å and 3.772(2) Å] in these 
hexagonal channels interacting with neighbouring methyl groups renders interpenetration 
impossible. LIBDMG2 is isostructural with LICDMG2. 
 
 LICPRO2: Each lithium cation is bridged by four carboxylates [Li-O: 1.9341(18) 
Å and 1.9536(19) Å] to form a cationic dia net with hexagonal channels exhibiting 
diameters ranging from 10.1 Å to 12.5 Å, populated by the chloride anions [figure 4-
20(left)]. The framework is reinforced by hydrogen bonding between the carboxylate of 
one amino acid and the ammonium of an adjacent amino acid [N-H···O, 2.7404(15) Å]. 
The presence of pairs of chloride anions [N-H···Cl, 3.1322(12) Å] in these hexagonal 
channels interacting with neighbouring ammonium groups renders interpenetration 
impossible. 
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Figure 4-20. Hexagonal channels in dia nets of LICPRO2 (left) and LIBPRO2 
(right). 
 
 LIBPRO2: Each lithium cation is bridged by four carboxylates [Li-O: 1.939(2) Å 
and 1.974(3) Å] to form a cationic dia net with hexagonal channels exhibiting diameters 
ranging from 10.2 Å to 12.6 Å, populated by the bromide anions [figure 4-20(right)]. The 
framework is reinforced by hydrogen bonding between the carboxylate of one amino acid 
and the ammonium of an adjacent amino acid [N-H···O, 2.737(2) Å]. The presence of 
pairs of bromide anions [N-H···Br: 3.2769(15) Å] in these hexagonal channels 
interacting with neighbouring ammonium groups renders interpenetration impossible. 
LIBPRO2 is isostructural with LICPRO2. 
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Figure 4-21. Hexagonal channels in LINPRO2 (dia, top) and octagonal channels in 
LINPRO2 (ABW, bottom). 
 
 LINPRO2 (dia): Each lithium cation is bridged by four carboxylates [Li-O: 
1.921(12) Å, 1.937(12) Å, 1.959(13) Å and 1.965(12) Å] to form a cationic dia net with 
hexagonal channels exhibiting diameters ranging from 10.6 Å to 12.3 Å, populated by the 
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nitrate anions [figure 4-21(top)]. The framework is reinforced by hydrogen bonding 
between the carboxylate of one amino acid and the ammonium of an adjacent amino acid 
[N-H···O, 2.751(5) Å, 2.762(5) Å]. The presence of pairs of nitrate anions [N-H···O, 
2.741(6) Å, 2.870(6) Å, 3.046(6) Å] in these hexagonal channels interacting with 
neighbouring ammonium groups renders interpenetration impossible. 
 LINPRO2 (ABW): A combination of Li4(carboxylate)4 and Li8(carboxylate)8 
rings generate channels that lie parallel to the crystallographic a axis. When viewed down 
the crystallographic c axis, the presence of Li6(carboxylate)6 rings is evident.  Li-O bond 
distances in the range of 1.913(3) Å -1.976(3) Å occur in the 4- and 8-membered rings 
while Li-O bond distances in the range of 1.920(2) Å -1.976(3) Å are observed in the 6-
membered rings. Pairs of nitrate anions occupy the 8-membered ring channels and they 
are crystallographically ordered through N-H···O hydrogen bonding interactions 
[2.735(8)Å, 2.885(8)Å, 3.005(8)Å]. The dimensions of the largest 8-membered ring 
channel are about twice that of an ABW zeolite as illustrated in figure 4-22. 
 Although the ABW form of LINPRO2 is stable at elevated temperatures, it 
converts to the diamondoid form, LINPRO2(dia), upon standing in mother liquor under 
ambient conditions. Grinding of the plate-like crystals of LINPRO2(ABW) also results in 
conversion to LINPRO2(dia) as determined by powder X-ray diffraction (PXRD). 
Interestingly, ABW zeolite has been observed as an intermediate phase in inorganic 
zeolite synthesis188. 
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Figure 4-22. Significant expansion of dimensions occurs because of the ditopic 
carboxylate linker in the ABW-type LiZMOM LINPRO2 when compared to 
prototypal ABW zeolite. 
 
 Whereas the Li-carboxylate bond distances observed in the structures reported 
herein exhibit a relatively narrow range, the Li-carboxylate-Li angles range from 117.78o 
[Li4(carboxylate)4 ring in LICSAR2] to 180o [Li8(carboxylate)8 ring in LINPRO2(ABW)] 
and are detailed in Table 4-3.  The majority of angles cluster around 150o, intermediate 
between those for linear and tetrahedral geometry, which is consistent with what would 
be needed to form a wider range of zeolitic structures. 
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Table 4-3. Analysis of Li-C-Li angles forming 4-, 6- and 8-membered ring motifs. 
 4-membered ring motif 
6-membered ring 
motif 
8-membered ring 
motif 
LICSAR2 117.78°, 157.08°   
LINBTN2 122.77°, 144.37°   
LICDMG2  153.27°  
LIBDMG2  153.27°  
LICPRO2  156.00°  
LIBPRO2  155.50°  
LINPRO2 (dia)  154.84°, 158.77°  
LINPRO2 (ABW) 122.13°, 148.72° 148.72°, 155.18°, 158.97° 
122.13°, 148.72°, 
155.18°, 158.97° 
ABW 149.4°, 156.8° 156.8°, 156.9°, 180° 149.4°, 180° 
 
4.3 Conclusion 
 19 crystal forms (13 cocrystals and 6 cocrystal hydrates) of lithium salts (chloride, 
bromide, nitrate) have been presented herein. Hydration appears to be a phenomenon in 
these ionic cocrystals, in particular, the 1:1 cocrystals. That the 1:1 cocrystals with 
lithium nitrate and the 1:2 cocrystals escape hydration suggests that perhaps hydration is 
predictable in this situation. Given their ubiquity, relevance and that many hydrates are 
discovered due to the adventitious water molecules, it should be unsurprising that a 
number of researchers have addressed the frequency189, formation190 and the water 
environment of organic crystalline hydrates191-194 and crystalline hydrates have been 
classified according to their structure or energetics.194  Morris and Rodriguez-Hornedo195 
proposed a classification system whereby hydrates are subdivided into three classes (1) 
channel hydrates in which water molecules interact with each other to form tunnels 
within the crystal lattice, (2) isolated site hydrates in which water molecules are not 
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directly hydrogen bonded to each other, (3) metal ion associated hydrates in which water 
molecules form strong interactions with transition metals or alkali metals. The 1:1 
cocrystal hydrates fall into the third category where water molecules are coordinated to 
lithium cations, as evidenced from the crystal structures. The isolation and 
characterization of both the anhydrate and hydrate will be advantageous to discern the 
hydration trend. In fact, both the anhydrate and monohydrate of LICBAL are isolable. 
Whereas a coordinated chloride anion [Li-Cl: 2.304 (3) Å] is observed in the anhydrate, a 
water molecule displaces the chloride and coordinates to the lithium cation [Li-O: 
2.002(3) Å] in the monohydrate. A comparison of the respective Li-Cl distance and Li-O 
distance confirms the strength of the Li-O bond over the Li-Cl bond. This is expected 
from the oxophilic character of the lithium cation and also explains why lithium chloride 
is a hygroscopic solid. The coordination sphere of lithium cations is surrounded by 4 
oxygen atoms in the 1:1 cocrystals with lithium nitrate and the 1:2 cocrystals and 
therefore hydration cease in the solid state. 
 These crystal forms of lithium salts have generated a rich diversity of structure 
types from 0-periodic to 3-periodic. All 1:1 cocrystals are assembled into 1-periodic 
chains, including a discrete supermolecule that is hydrogen bonded into a chain in 
LICDMG. The only exception is LINPRO which exists as a mixed ligand dia net, where 
the nitrate anion plays the same role of a bridging ligand as the carboxylate moiety of the 
zwitterion. The architectures constructed from 1:2 cocrystals feature 2-periodic and 3-
periodic nets, composed of 4-, 6- and 8-membered Lin(carboxylate)n (n=4, 6, 8) rings, 
reminiscent of square grids, dia nets and a zeolitic ABW net. This approach consists of 
one-step synthesis from readily available starting materials and should be general because 
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of the modular nature of these compounds and the ready availability of amino acids and 
counteranions. The use of larger anions and/or templates coupled with the expected 
diversity of Li-carboxylate-Li angles will envisage a range of LiZMOMs that parallels 
the structural diversity seen in inorganic zeolites and zeolitic metal-organic materials. 
 
4.4 Materials and Methods 
 All chemicals purchased were used as received without further purification. 
 
4.4.1 Synthesis of Crystal Forms of Lithium Salts 
 LICSAR: Lithium chloride (100.0 mg, 2.36 mmol) and sarcosine (211.0 mg, 
2.36 mmol) were dissolved in 0.5 mL of deionised water and left for slow evaporation. 
Colourless plate-like crystals (200 mg, m.p. 245°C) were harvested after three days. 
 LINSAR: Lithium nitrate (413.4 mg, 6.0 mmol) and sarcosine (534.5 mg, 
6.0 mmol) were dissolved in 1 mL of deionised water. It was maintained on the hot plate 
until crystals emerged from the hot solution. Colorless crystals (368.4 mg, 208°C) were 
collected from the hot solution. 
 LICDMG: Lithium chloride (50.0 mg, 1.18 mmol) and N,N-dimethylglycine 
(122.0 mg, 1.18 mmol) were dissolved in 0.75 mL of hot deionised water. It was left for 
slow evaporation. Colourless block crystals (101 mg, 272°C) were harvested after one 
month. 
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 LINDMG: Lithium nitrate (413.4 mg, 6.0 mmol) and N,N-dimethylglycine 
(618 mg, 6.0 mmol) were dissolved in 3 mL of hot deionised water. It was maintained on 
the hot plate until crystals emerged from the hot solution. Colorless plates (595 mg, 
202°C) were collected from the hot solution. 
 LICBTN: Lithium chloride (1.00 g, 23.6 mmol) and betaine (2.76 g, 23.6 mmol) 
were dissolved in 1 mL of hot deionised water. . It was maintained on the hot plate until 
crystals emerged from the hot solution. Colorless block crystals were collected from the 
hot solution. The crystals were very hygroscopic and deliquesced into liquid rapidly once 
out of the mother liquor. 
 LICBAL-anhydrate: Lithium chloride (1.00 g, 23.6 mmol) and β-alanine (2.11 g, 
23.6 mmol) were dissolved in 2 mL of hot deionised water. It was maintained on the hot 
plate until crystals emerged from the hot solution. Colourless rod crystals (2143 mg, 
252°C) were collected from the hot solution. 
 LICBAL: Lithium chloride (1.00 g, 23.6 mmol) and β-alanine (2.11 g, 
23.6 mmol) were dissolved in 2 mL of hot deionised water. It was maintained on the hot 
plate until crystals emerged from the hot solution. The contents were allowed to cool. The 
mother liquor was decanted and 0.5 mL of deionised water was added. The colourless 
plate crystals (1910 mg, 252°C) were harvested the next day. 
 LICABA: Lithium chloride (1.00 g, 23.6 mmol) and 4-aminobutyric acid (2.44 g, 
23.6 mmol) were dissolved in 2 mL of hot deionised water. It was maintained on the hot 
plate until crystals emerged from the hot solution. Colourless rod crystals (2244 mg, 
241°C) were collected from the hot solution. 
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 LICPRO: Lithium chloride (200.0 mg, 4.72 mmol) and L-proline (544.0 mg, 
4.72 mmol) were dissolved in 0.75 mL of deionised water and left for slow evaporation. 
Colourless plate crystals (609 mg, 281°C) were harvested after three days. 
 LIBPRO: Lithium bromide (1.00 g, 11.5 mmol) and L-proline (1.33 g, 11.5 mmol) 
were dissolved in 2 mL of hot deionised water. It was maintained on the hot plate until 
crystals emerged from the hot solution. Colourless block crystals (1427 mg, 280°C) were 
harvested from the hot solution. 
 LINPRO: Lithium nitrate (413.4 mg, 6.0 mmol) and L-proline (690.0 mg, 
0.599 mmol) were dissolved in 1.5 mL of deionised water and was maintained on the hot 
plate until crystals emerged from the hot solution. Colorless plates (473.8 mg, 232°C) 
were collected from the hot solution. 
 LICSAR2: Lithium chloride (0.5 g, 11.8 mmol) and sarcosine (3.15 g, 35.4 mmol) 
were dissolved in 2 mL of hot deionised water. It was maintained on the hot plate until 
crystals emerged from the solution. Colourless block crystals (1213 mg, 247oC) were 
harvested from the hot solution. 
 LINBTN2: Lithium nitrate (413.4 mg, 6.0 mmol) and betaine (1405.6 mg, 
12.0 mmol) were dissolved in 2 mL of hot deionised water. It was maintained on the hot 
plate until crystals emerged from the hot solution. Colorless plates (357 mg, 286oC) were 
collected from the hot solution. 
 LICDMG2: Lithium chloride (0.5 g, 11.8 mmol) and N,N-dimethylglycine 
(2.44 g, 23.6 mmol) were dissolved in 3 mL of hot deionised water. It was maintained on 
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the hot plate until crystals emerged from the hot solution. Colourless block crystals 
(1488 mg) were collected from the hot solution. 
 LIBDMG2: Lithium bromide (0.5 g, 5.76 mmol) and N,N-dimethylglycine 
(1.19 g, 11.5 mmol) were dissolved in 2 mL of hot deionised water. It was maintained on 
the hot plate until crystals emerged from the hot solution. Colourless block crystals 
(696 mg, 289ºC) were collected from the hot solution. 
 LICPRO2: Lithium chloride (0.50 g, 11.8 mmol) and L-proline (2.72 g, 
23.6 mmol) were dissolved in 2 mL of hot deionised water. It was maintained on the hot 
plate until crystals emerged from the hot solution. Colourless block crystals (1266 mg, 
250oC) were harvested from the hot solution. 
 LIBPRO2: Lithium bromide (0.50 g, 5.76 mmol) and L-proline (1.33 g, 
11.5 mmol) were dissolved in 2 mL of hot deionised water. It was maintained on the hot 
plate until crystals emerged from the hot solution. Colourless block crystals (861 mg, 
257oC) were collected from the hot solution. 
 LINPRO2: Lithium nitrate (413.4 mg, 6.0 mmol) and L-proline (1381.2 mg, 
12.0 mmol) were dissolved in 2 mL of hot deionised water. It was maintained on the hot 
plate until crystals emerged from the hot solution. Colorless plates (LINPRO2, ABW) 
were collected from the hot solution which converted to rhombohedral crystals 
(LINPRO2, dia, 603 mg) once they are removed from the hot plate. 
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4.4.2 Crystal Form Characterization 
 Single crystals suitable for X-ray diffraction were selected using an optical 
microscope. The X-ray diffraction data were collected using Bruker-AXS 
SMART-APEX/APEXII CCD diffractometer with monochromatized Cu Kα radiation (λ 
= 1.54178 Å) for all crystal samples.  Indexing was performed using SMART v5.62537a 
or using APEX 2008v1-0.37b Frames were integrated with SaintPlus 7.5138 software 
package. Absorption correction was performed by multiscan method implemented in 
SADABS.39 The structures were solved using SHELXS-97 (Direct methods) and refined 
using SHELXL-97 (full matrix nonlinear least-squares) contained in SHELXTL v6.1040 
and WinGX v1.70.0141-43 program packages. All non-hydrogen atoms were refined 
anisotropically. 
 A Bruker AXS D8 X-ray powder diffractometer was used for all PXRD 
measurements with experimental parameters as follows: Cu Kα radiation (λ = 1.54056 Å); 
40 kV and 30 mA; detector type: scintillation type; scanning interval: 3° - 40° 2θ; time 
per step: 0.5 s. The experimental PXRD patterns and calculated PXRD patterns from 
single crystal structures were compared to confirm the composition of bulk materials. 
 Thermal analysis was performed on a TA Instruments DSC 2920 differential 
scanning calorimeter. Aluminum pans were used for all samples and the instrument was 
calibrated using an indium standard. For reference, an empty pan sealed in the same way 
as the sample was used. Using inert nitrogen conditions, the samples were heated in the 
DSC cell from 30°C to 300°C at a rate of 10°C/min. 
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 A Perkin-Elmer STA 6000 Simultaneous Thermal Analyzer was used to conduct 
thermogravimetric analysis. Open alumina crucibles were used to heat the samples from 
30°C to 300°C at a rate of 10°C/min under a nitrogen stream. 
 Characterization of the cocrystals by FTIR was accomplished with a Nicolet 
Avatar 320 FT-IR instrument. Sample amounts of 1-2 mg were used, and spectra were 
measured over the range of 4000-400 cm-1 and analyzed using EZ Omnic software. 
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Table 4-4. Selected hydrogen bond parameters for 1:1 ionic cocrystals. 
Compound Hydrogen bond d (H···A) / Å D (D···A) / Å θ / ° 
LICSAR 
O(3)-H(1O)•••O(2)#1 2.305 (5) 2.951 (7) 170.6 (5) 
N(6)-H(1N)•••Cl(1)#7 2.249 (2) 3.145 (5) 168.9 (3) 
N(6)-H(2N)•••Cl(1) 2.224 (2) 3.114 (5) 167.1 (3) 
#1 x+1,y,z    #2 x+1/2,-y+1/2,-z+2    #3 x+1,y-1,z 
 #4 x-1,y,z    #5 x-1/2,-y+1/2,-z+2    #6 x-1,y+1,z 
 #7 x,y+1,z 
LINSAR N(1)H(1B)•••O(3) 2.012 (2) 2.896 (3) 167.2 (1) N(1)H(1A)•••O(3) 2.197 (2) 2.918 (3) 136.8 (1) 
LICDMG 
N(1)-H(1)•••Cl(1)#2 2.430 (19) 3.2204 (12) 148.8 (15) 
O(1)-H(2)•••Cl(1)#3 2.41 (3) 3.1452 (12) 175 (2) 
O(2)-H(5)•••O(3)#2 1.96 (3) 2.7543 (14) 174 (2) 
O(2)-H(4)•••Cl(1)#2 2.38 (2) 3.1686 (11) 169 (2) 
O(1)-H(3)•••Cl(1)#4 2.29 (3) 3.1264 (12) 177 (2) 
#1 -x,-y,-z+1    #2 x-1,y,z    #3 -x+1,-y+1,-z+2 
 #4 x-1,y-1,z 
LINDMG N(1)H(7)•••O(5) 1.9912 2.8349 (1) 158.49 
LICBTN 
O(4)-H(3)•••Cl(1)#3 2.47 (5) 3.178 (2) 165 (5) 
O(3)-H(2)•••Cl(2)#4 2.30 (3) 3.120 (2) 168 (3) 
O(4)-H(4)•••Cl(2)#5 2.37(5) 3.117 (2) 163 (4) 
O(3)-H(1)•••Cl(1)#6 2.33 (5) 3.065 (2) 168 (4) 
#1 -x+1,-y,z+1/2    #2 -x+1,-y,z-1/2    #3 x-1/2,-y-1/2,z 
 #4 x+1/2,-y+1/2,z    #5 x,y-1,z    #6 x,y+1,z 
LICBAL-
anhydrate 
N(1)-H(1A)•••Cl(1)#4 2.62 3.2433 (14) 128.3 
N(1)-H(1B)•••Cl(1)#5 2.32 3.1983 (14) 168.6 
N(1)-H(1C)•••O(2)#4 1.95 2.8251 (17) 167.2 
#1 -x,-y+2,-z+1    #2 -x+1,-y+2,-z+1    #3 -x+1/2,y-1/2,-z+1/2 
 #4 x+1/2,-y+3/2,z+1/2    #5 x-1/2,-y+3/2,z+1/2 
LICBAL 
O(1)-H(1)•••Cl(1)#5 2.41 (3) 3.2458 (14) 179 (2) 
O(1)-H(2)•••Cl(1)#6 2.36 (3) 3.1262 (17) 170 (3) 
N(1)-H(4)•••Cl(1)#7 2.53 (2) 3.2475 (15) 135.9 (18) 
N(1)-H(3)•••O(3) 2.44 (4) 2.980 (2) 120 (3) 
N(1)-H(5)•••Cl(1)#9 2.38 (3) 3.222 (2) 167 (3) 
#1 -x+5/2,y+1/2,-z+1/2    #2 x,y+1,z    #3 x,y-1,z 
 #4 -x+5/2,y-1/2,-z+1/2    #5 x+1,y,z    #6 x+1,y-1,z 
 #7 -x+1,-y+1,-z+1    #8 x-1,y+1,z    #9 -x+1,-y,-z+1 
LICABA 
N(1)-H(1A)•••Cl(1)#5 2.32 3.1516 (13) 155.9 
N(1)-H(1B)•••Cl(1)#6 2.33 3.1886 (13) 163.0 
N(1)-H(1C)•••O(2)#7 1.92 2.7970 (16) 166.6 
#1 x,y+1,z    #2 -x+5/2,y+1/2,-z+1/2    #3 x,y-1,z 
 #4 -x+5/2,y-1/2,-z+1/2    #5 -x+2,y+1,-z+1/2    #6 x-1/2,-y+1/2,z-1/2 
 #7 -x+2,-y+2,-z 
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LICPRO 
O(3)-H(11)•••Cl(1)#5 2.32 3.234 (3) 161.1 
O(3)-H(12)•••Cl(1)#6 2.23 3.194 (3) 171.6 
N(1)-H(1)•••Cl(1) 2.42 3.187 (3) 144.6 
N(1)-H(2)•••Cl(1)#4 2.69 3.336 (3) 128.5 
#1 -x+1,y-1/2,-z+2    #2 x,y-1,z    #3 -x+1,y+1/2,-z+2 
 #4 x,y+1,z    #5 -x+1,y+1/2,-z+1    #6 -x+1,y-1/2,-z+1 
LIBPRO 
O(17)-H(17A)•••Br(2) 2.63 (6) 3.345 (3) 167 (6) 
O(17)H(17B)•••Br(2) 2.40 (5) 3.312 (3) 168 (4) 
O(18)-H(18B)•••Br(1) 2.64 (6) 3.353 (3) 163 (6) 
O(18)-H(18A)•••Br(1) 2.42 (4) 3.322 (3) 177 (3) 
N(16)-H(16B)•••Br(1) 2.76 (3) 3.326 (3) 123 (2) 
N(16)H(16A)•••Br(1) 2.47 (4) 3.277 (3) 154 (3) 
N(8)-H(8A)•••Br(2) 2.53 (4) 3.289 (3) 144 (3) 
LINPRO 
N(1)-H(1A)•••O(12)#5 1.95 (2) 2.842 (2) 165 (2) 
N(1)-H(1B)•••O(1)#2 2.02 (2) 2.898 (2) 161 (2) 
#1 x-1/2,-y+3/2,-z    #2 -x+2,y-1/2,-z+1/2    #3 -x+2,y+1/2,-z+1/2 
 #4 x+1/2,-y+3/2,-z    #5 -x+5/2,-y+1,z+1/2 
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Table 4-5. Selected hydrogen bond parameters for 1:2 ionic cocrystals. 
Compound Hydrogen bond d (H···A) / Å D (D···A) / Å θ / ° 
LICSAR2 
N(1)-H(1A)•••Cl(1)#5 2.195 (2) 3.1011 (1) 159.9 (1) 
N(1)-H(1B)•••Cl(1)#6 2.281 (2) 3.1549 (1) 166.4 (1) 
N(2)-H(4A)•••O(3)#4 1.85 (2) 2.7244 (2) 164.4 (2) 
N(2)-H(4B)•••O(2)#4 2.01 (2) 2.8878 (2) 161.6 (2) 
#1 -x+5/2,y+1/2,z    #2 -x+5/2,y-1/2,z    #3 x+1/2,-y+1/2,-z+1 
 #4 x-1/2,-y+1/2,-z+1    #5 x+1,y,z    #6 x+1/2,y,-z+1/2 
LICDMG2 N(1)-H(1N)•••O(2)#1 1.79 2.742 (2) 168.5 #1 x-1/4,-y+1/4,z-1/4 
LIBDMG2 
N(1)-H(1)•••O(2)#5 1.85 2.747 (2) 161.3 
#1 -x+3/4,y+1/4,z-1/4    #2 -x+1/2,-y+1/2,z    #3 x-1/4,-y+3/4,z+1/4 
 #4 -x+3/4,y-1/4,z+1/4    #5 x+1/4,-y+3/4,z-1/4 
LICPRO2 
N(1)-H(1B)•••Cl(1)#1 2.22 3.1322 (12) 172.9 
N(1)-H(1A)•••O(2)#2 1.82 2.7404 (15) 175.4 
#1 x,y+1,z    #2 x-1/2,-y+3/2,-z+3/4 
LIBPRO2 
N(1)-H(1A)•••Br(1)#1 2.36 3.2769 (15) 174.6 
N(1)-H(1B)•••O(1)#2 1.82 2.737 (2) 175.1 
#1 x,y-1,z    #2 x+1/2,-y+1/2,-z-1/4 
LINPRO2 
(dia) 
N(3)-H(3A)•••O(2)#5 1.93 2.741 (6) 145.8 
N(3)-H(3B)•••O(5)#1 1.85 2.762 (5) 170.3 
N(4)-H(4A)•••O(4)#3 1.85 2.751 (5) 167.0 
N(4)-H(4B)•••O(2)#6 2.26 2.870 (6) 123.2 
N(4)-H(4B)•••O(1)#6 2.13 3.046 (6) 171.2 
#1 x-1/2,-y+3/2,-z+1    #2 -x+2,y-1/2,-z+1/2    #3 -x+2,y+1/2,-z+1/2 
 #4 x+1/2,-y+3/2,-z+1    #5 -x+3/2,-y+1,z-1/2    #6 -x+5/2,-y+2,z-1/2 
LINPRO2 
(ABW) 
N(3)-H(3C)•••O(4)#1 1.88 2.791 (2) 170.4 
N(3)-H(3D)•••O(13)#2 1.92 2.830 (2) 168.9 
N(3)-H(3D)•••O(14)#2 2.37 3.054 (2) 131.0 
N(1)-H(1A)•••O(11)#3 2.10 2.998 (2) 166.4 
N(1)-H(1B)•••O(12)#2 2.36 3.010 (2) 127.4 
N(1)-H(1B)•••O(10)#2 2.36 3.060 (2) 132.5 
N(2)-H(2C)•••O(1) 1.91 2.783 (2) 156.9 
N(2)-H(2C)•••O(3) 2.19 2.688 (2) 113.1 
N(2)-H(2D)•••O(8)#4 1.81 2.722 (2) 169.2 
N(4)-H(21A)•••O(10) 2.03 2.849 (2) 147.0 
N(4)-H(21A)•••O(9) 2.31 2.971 (2) 128.8 
N(4)-H(21B)•••O(5) 1.87 2.775 (2) 166.3 
#1 -x,y+1/2,-z+1/2    #2 -x+1,y+1/2,-z+1/2    #3 -x+1/2,-y+2,z+1/2 
 #4 x-1/2,-y+3/2,-z+1 
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Table 4-6. Crystallographic data for 1:1 ionic cocrystals. 
 LICSAR LINSAR LICDMG LINDMG 
Formula C3H9ClLiNO3 C3H7LiN2O5 C4H13ClLiNO4 C4H9LiN2O5 
MW 149.50 158.05 181.54 172.07 
Crystal system Orthorhombic Orthorhombic Triclinic Orthorhombic 
Space group P212121 P212121 P1ത Fdd2 
a (Å) 4.9169 (2) 5.0816 (5) 7.2090 (1) 21.7388 (6) 
b (Å) 5.2917 (2) 10.7057 (9) 7.5745 (2) 29.0098 (8) 
c (Å) 27.938 (1) 12.5344 (10) 9.0100 (2) 4.9930 (2) 
 (deg) 90 90 110.746 (1) 90 
 (deg) 90 90 93.170 (1) 90 
 (deg) 90 90 103.709 (1) 90 
V /Å3 726.91 (5) 681.9 (1) 441.698 (16) 3148.78 (18) 
Dc/mg m-3 1.366 1.539 1.365 1.452 
Z 4 4 2 16 
2 range 3.16 to 67.46 5.43 to 66.13 5.31 to 65.96 5.08 to 67.58 
Nref./Npara. 1288 / 85 1153 / 101 1466 / 123 1190 / 145 
T /K 100 (2) 100 (2) 100 (2) 100 (2) 
R1 [I>2sigma(I)] 0.0672 0.0384 0.0293 0.0269 
wR2 0.1717 0.1079 0.0828 0.0812 
GOF 1.188 0.869 1.393 0.744 
Abs coef. 4.186 1.259 3.624 1.137 
 LICBTN LICBAL-anhydrate LICBAL LICABA 
Formula C5H15Cl2Li2NO2 C3H7ClLiNO2 C3H9ClLiNO3 C4H9ClLiNO2 
MW 237.91 131.47 149.50 145.51 
Crystal system Orthorhomic Monoclinic Monoclinic Monoclinic 
Space group Pna21 P21/n P21/n C2/c 
a (Å) 11.8788 (4) 5.0510 (2) 6.6716 (9) 20.0021 (4) 
b (Å) 6.1712 (2) 13.2649 (5) 5.0400 (8) 4.8815 (1) 
c (Å) 15.3296 (5) 8.9413 (3) 19.816 (3) 17.0417 (6) 
 (deg) 90 90 90 90 
 (deg) 90 96.721 (2) 95.888 (7) 124.929 (1) 
 (deg) 90 90 90 90 
V /Å3 1123.76 (6) 594.96 (4) 662.78 (16) 1364.21 (6) 
Dc/mg m-3 1.407 1.468 1.498 1.417 
Z 2 4 4 8 
2 range 5.77 to 67.63 6.00 to 67.81 4.49 to 67.91 5.39 to 68.66 
Nref./Npara. 1790 / 146 1045 / 74 1156 / 102 1214 / 83 
T /K 100 (2) 100 (2) 100 (2) 100 (2) 
R1 [I>2sigma(I)] 0.0333 0.0284 0.0292 0.0299 
wR2 0.0757 0.0776 0.0841 0.0780 
GOF 1.080 1.361 1.516 1.104 
Abs coef. 5.104 4.909 4.591 4.335 
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Table 4-7. Crystallographic data for 1:1 ionic cocrystals (continued). 
 LICPRO LIBPRO LINPRO 
Formula C5H11ClLiNO3 C5H11BrLiNO3 C5H9LiN2O5 
MW 175.54 220.00 184.08 
Crystal system Monoclinic Monoclinic Orthorhombic 
Space group P21 P21 P212121 
a (Å) 7.7692 (12) 11.2473 (3) 9.0947 (4) 
b (Å) 5.1020 (9) 5.1316 (1) 9.2876 (5) 
c (Å) 10.3795 (16) 14.9547 (4) 9.5743 (5) 
 (deg) 90 90 90 
 (deg) 105.458 (9) 104.395 (1) 90 
 (deg) 90 90 90 
V /Å3 396.54 (11) 836.04 (4) 808.72 (7) 
Dc/mg m-3 1.470 1.748 1.512 
Z 2 4 4 
2 range 4.42 to 66.91 3.05 to 67.98 6.64 to 67.56 
Nref./Npara. 1097 / 100 2675 / 231 1406 / 124 
T /K 100 (2) 100 (2) 100 (2) 
R1 [I>2sigma(I)] 0.0312 0.0200 0.0290 
wR2 0.0862 0.0502 0.0739 
GOF 1.147 1.102 1.052 
Abs coef. 3.928 6.386 1.151 
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Table 4-8. Crystallographic data of 1:2 ionic cocrystals. 
 LICSAR2 LINBTN2 LICDMG2 LIBDMG2 
Formula C6H14ClLiN2O4 C10H22LiN3O7 C8H18ClLiN2O4 C8H18BrLiN2O4 
MW 220.58 303.25 248.63 293.09 
Crystal system Orthorhombic Monoclinic Orthorhombic Orthorhombic 
Space group Pbca P21/c Fdd2 Fdd2 
a (Å) 9.5197 (1) 16.0472 (16) 14.0427 (5) 14.0912 (2) 
b (Å) 9.9275 (1) 8.4767 (10) 14.6533 (5) 14.9035 (2) 
c (Å) 21.7783 (2) 10.8836 (11) 12.4822 (4) 12.5426 (2) 
 (deg) 90 90 90 90 
 (deg) 90 103.731 (6) 90 90 
 (deg) 90 90 90 90 
V /Å3 2058.20 (4) 1438.2 (3) 2568.49 (15) 2634.05 (7) 
Dc/mg m-3 1.424 1.401 1.286 1.478 
Z 8 4 8 8 
2 range 4.06 to 67.95 2.83 to 66.56 5.62 to 68.02 5.58 to 66.35 
Nref./Npara. 1838 / 145 2484 / 196 1080 / 76 1114 / 77 
T /K 100 (2) 100 (2) 100 (2) 100 (2) 
R1 [I>2sigma(I)] 0.0274 0.0408 0.0312 0.0178 
wR2 0.0786 0.1134 0.0726 0.0464 
GOF 1.031 1.023 0.994 1.089 
Abs coef. 3.248 0.992 2.660 4.282 
 LICPRO2 LIBPRO2 LINPRO2 (dia) LINPRO2 (ABW) 
Formula C10H18ClLiN2O4 C10H18BrLiN2O4 C10H18LiN3O7 C10H18LiN3O7 
MW 272.65 317.11 299.21 299.21 
Crystal system Tetragonal Tetragonal Orthorhombic Orthorhombic 
Space group P41212 P41212 P212121 P212121 
a (Å) 9.0791 (1) 9.1703 (3) 9.5219 (9) 11.0448 (3) 
b (Å) 9.0791 (1) 9.1703 (3) 9.5664 (9) 12.0393 (3) 
c (Å) 15.4104 (2) 15.5694 (14) 15.0812 (12) 20.2019 (5) 
 (deg) 90 90 90 90 
 (deg) 90 90 90 90 
 (deg) 90 90 90 90 
V /Å3 1270.28 (3) 1309.30 (14) 1373.8 (2) 2686.28 (12) 
Dc/mg m-3 1.426 1.609 1.447 1.480 
Z 4 4 4 8 
2 range 5.66 to 67.91 5.60 to 68.18 2.93 to 65.90 4.27 to 65.93 
Nref./Npara. 1150 / 84 1182 / 83 2347 / 191 4505 / 379 
T /K 100 (2) 100 (2) 100 (2) 100 (2) 
R1 [I>2sigma(I)] 0.0229 0.0181 0.0576 0.0314 
wR2 0.0662 0.0447 0.1454 0.0799 
GOF 1.022 1.078 1.046 1.045 
Abs coef. 2.745 4.362 1.038 1.061 
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Chapter 5. Conclusions and Future Directions 
 
5.1 Conclusions 
 The power of the supramolecular heterosynthon approach to generate cocrystals is 
once again demonstrated using ellagic acid. 17 crystal forms (5 cocrystals, 7 cocrystal 
solvates/hydrates and 5 solvates) of ellagic acid have been isolated and characterized by 
solid state analytical techniques. The crystal forms of ellagic acid reveal its compatibility 
with a diverse variety of functional groups in pyridine, imidazole, pyrazole, carboxylate 
and carbonyl moieties. The discovery of ellagic acid solvates while serendipitous is not 
totally unexpected since ellagic acid has an imbalance of hydrogen bond donors over 
acceptors and thus demonstrates its affinity for solvent molecules with superior hydrogen 
bond acceptor capabilities. Solvation/hydration persists after cocrystal formation if the 
imbalance remains. This obeys Etter’s first rule of hydrogen bonding196 that “all good 
proton donors and acceptors are used in hydrogen bonding”, as originally put forth by 
Donohue197, is satisfied. Hence the synergistic incorporation of the phenol-carbonyl 
supramolecular heterosynthon resulted in the cocrystal solvates of ellagic acid with 
isonicotinamide and theophylline. This synergism put polyphenols such as ellagic acid in 
a favourable position to be included in a cocrystal former library for cocrystal screening 
experiments since APIs routinely contain multiple functional groups. 
 The motivation to diversify the crystal forms of lithium salts stems from the 
pharmacological properties of lithium that consistently reduce suicidality in recurrent 
unipolar major depressive disorder and in bipolar disorder. To engineer ionic cocrystals 
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of lithium salts, the coordination chemistry of the lithium cation has been immensely 
helpful. The oxophilic character of lithium points to oxygen based ligands such as the 
carboxylate as a good cocrystal former. That the carboxylate is negatively-charged means 
the carboxylate moiety has to be derived from an amino acid so that it is an overall 
neutral molecule. In addition, that there are active transporters to facilitate the movement 
of amino acids across the blood brain barrier implies that intuitively, amino acids may be 
the appropriate cocrystal formers to target ionic cocrystals of lithium salts and potentially 
facilitate the passage of the lithium cations across the blood brain barrier. 
 The choice of the lithium-to-amino acid stoichiometry dictates the periodicity of 
the crystal structure. Equimolar quantities of lithium salts and amino acids yield 1-
periodic structures with the exception of LICDMG (a discrete supermolecule that is 
hydrogen bonded into a 1-periodic chain) and LINPRO (a mixed ligand 3-periodic dia 
net). The construction of 2-periodic and 3-periodic nets is instead observed in 1:2 
cocrystals of lithium salts and amino acids to generate cationic square grids, dia nets and 
a zeolitic ABW net. These architectures are characterized by the formation of 4-, 6- and 
8-membered Lin(carboxylate)n (n=4, 6, 8) rings with a wide range of Li-carboxylate-Li 
angles. Dia nets are prone to interpenetration but the presence of pairs of counterions and 
the bulkiness of the amino acid substituents precludes interpenetration in the LiDMOMs. 
The zeolitic ABW net is the first example of a LiZMOM and features the combination of 
4-, 6- and 8-membered Lin(carboxylate)n (n=4, 6, 8) rings. The modular nature of these 
compounds coupled with larger anions will envisage a range of LiZMOMs that parallels 
the structural diversity seen in inorganic zeolites and zeolitic metal-organic materials. 
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5.2 Future Directons 
 While the phenol-pyridine, phenol-imidazole, phenol-pyrazole and phenol-
carboxylate supramolecular heterosynthons have been the target of crystal engineering 
studies, the phenol-carbonyl supramolecular heterosynthon is still relatively unexplored. 
While ε-caprolactam (supramolecularly similar to a carboxylic acid) and urea are not the 
best models for a carbonyl group such as a ketone, the phenol-carbonyl supramolecular 
heterosynthon is observed nonetheless. 
 
Figure 5-1. Triclinic modification of quinhydrone. 
 
 That the phenol-carbonyl supramolecular heterosynthon is not exploited in 
cocrystal design is perhaps surprising since it is featured in the prototypal cocrystal in 
quinhydrone198 (1:1 cocrystal of quinone and hydroquninone) by Wöhler in 1844. 
Further, benzophenone was used to prepare a cocrystal with diphenylamine.199 These 
cocrystals were discovered without the benefit of single crystal X-ray crystallography. 
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The power of X-ray crystallography200-201 undoubtedly elucidates the carbonyl group to 
be the hydrogen bond acceptor for these cocrystals. Perhaps ellagic acid can form a 
cocrystal with benzophenone. In line with using pharmaceutically acceptable cocrystal 
formers, flavone202 may be an excellent choice. 
 
Figure 5-2. Carbonyl as the hydrogen bond acceptor in the cocrystal of 
diphenylamine and benzophenone. 
 
 All 1:1 cocrystals of lithium nitrate and amino acids are capable of generating 
mixed ligand dia nets or square grids but only LINPRO is observed as a mixed ligand dia 
net. Nature tunes the polymorphic selectivity of silica by varying temperature. Perhaps a 
similar approach can be used to hunt for other mixed ligand dia nets or square grids. 
While these may be of pure academic interest, the ability to control the crystal structure is 
an example of crystal engineering at this finest and is potentially useful to the control of 
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polymorphic selectivity. However, that the mapping of the phase diagram does not 
guarantee the preparation and isolation of a particular crystal form203 must not discourage 
us in our endeavours but serve as the motivational tool to refine our skills and better our 
knowledge at crystallization. 
 
5.3 Crystal Engineering and Crystallization 
 “… crystal engineering, which is defined as the understanding of intermolecular 
interactions in the context of crystal packing and in the utilization of such understanding 
in the design of new solids with desired physical and chemical properties…”204 
Gautam R. Desiraju 
“…, the last step (precipitating good single crystals) remains a black art.”205 
Philip Ball 
 “… there is still a great deal of black art (art, not magic!) and I might add skill, 
experience and chemical intuition in making them”206 
Joel Bernstein 
 I close with some noteworthy quotes. I have not deliberated on crystal 
engineering207 thus far, even though crystal engineering is reflected in the title of this 
dissertation. Using Desiraju’s definition of crystal engineering, the understanding of 
intermolecular (non-covalent and ionic) interactions have been documented and are 
exploited to design the molecular and ionic cocrystals presented in this dissertation. I can 
identify with the comments by Bernstein (in response to Ball) that undoubtedly mirrors 
one of the toughest challenges I had to overcome. The variety of organic, inorganic and 
hybrid solids is ever increasing. Crystal engineering is a science but crystallization 
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remains an art, but no longer a dark art. The concerted operation of the art of 
crystallization and the craft of crystal engineering is imminent to achieve the final prize, 
the desired crystalline material. 
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Appendix 1. Solid state characterization data for ELANAM 
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Appendix 2. Solid state characterization data for ELAINM•1.7H2O 
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Appendix 3. Solid state characterization data for ELAINM•4NMP 
0 5 10 15 20 25 30 35 40 45
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
R
el
at
iv
e 
In
te
ns
ity
2
Calculated
Experimental
 
  
63
8.
18
65
7.
49
76
1.
10
81
2.
85
88
5.
21
91
5.
75
10
08
.6
9
10
46
.0
3
10
92
.5
0
11
80
.6
7
13
04
.1
1
13
43
.4
3
14
13
.3
8
14
43
.1
7
15
05
.4
8
15
56
.5
4
16
05
.9
6
16
66
.0
7
16
91
.0
3
17
25
.4
4
 70
 72
 74
 76
 78
 80
 82
 84
 86
 88
 90
 92
 94
 96
 98
 100
%
T
 1000   2000   3000   4000  
Wavenumbers (cm-1)
163 
 
Appendix 4. Solid state characterization data for ELAINM•4DMA 
0 5 10 15 20 25 30 35 40 45
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
R
el
at
iv
e 
In
te
ns
ity
2
Calculated
Experimental
  
 
  
164 
 
Appendix 5. Solid state characterization data for ELACAF•H2O 
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Appendix 6. Solid state characterization data for ELATPH•0.13H2O 
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Appendix 7. Solid state characterization data for ELATPH•2DMA 
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Appendix 8. Solid state characterization data for ELADMP 
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Appendix 9. Solid state characterization data for ELASAR 
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Appendix 10. Solid state characterization data for ELADMG 
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Appendix 11. Solid state characterization data for ELACAP  
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Appendix 12. Solid state characterization data for ELAURE•2NMP 
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Appendix 13. Solid state characterization data for ELADMA4 
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Appendix 14. Solid state characterization data for ELADMA2 
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Appendix 15. Solid state characterization data for ELADMSO2 
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Appendix 16. Solid state characterization data for ELANMP2 
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Appendix 17. Solid state characterization data for ELAPG2 
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Appendix 18. Solid state characterization data for LICSAR 
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Appendix 19. Solid state characterization data for LINSAR 
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Appendix 20. Solid state characterization data for LICDMG 
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Appendix 21. Solid state characterization data for LINDMG 
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Appendix 22. Solid state characterization data for LICBAL-anhydrate 
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Appendix 23. Solid state characterization data for LICBAL 
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Appendix 24. Solid state characterization data for LICABA 
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Appendix 25. Solid state characterization data for LICPRO 
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Appendix 26. Solid state characterization data for LIBPRO 
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Appendix 27. Solid state characterization data for LINPRO 
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Appendix 28. Solid state characterization data for LICSAR2 
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Appendix 29. Solid state characterization data for LINBTN2 
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Appendix 30. Solid state characterization data for LICDMG2 
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Appendix 31. Solid state characterization data for LIBDMG2 
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Appendix 32. Solid state characterization data for LICPRO2 
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Appendix 33. Solid state characterization data for LIBPRO2 
0 5 10 15 20 25 30 35 40 45
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
R
el
at
iv
e 
In
te
ns
ity
2
Calculated
Experimental
 
 
 
  
60
3.
70
71
0.
59
76
2.
99
80
2.
07
85
4.
27
90
8.
28
95
8.
43
98
9.
50
10
49
.0
2
10
78
.8
6
11
91
.8
8
12
91
.3
5
13
35
.5
1
13
81
.0
7
14
01
.6
6
14
49
.8
0
15
93
.2
5
16
22
.2
7
16
44
.4
9
22
04
.9
7
24
98
.9
8
25
72
.3
7
26
57
.3
5
27
54
.8
2
29
26
.5
7
34
01
.2
7
142e LIBPRO2
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105
%
T
 1000   2000   3000   4000  
Wavenumbers (cm-1)
193 
 
Appendix 34. Solid state characterization data for LINPRO2 (dia) 
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